Skip to main content
Erschienen in: Clinical Pharmacokinetics 4/2003

01.04.2003 | Review Article

Pharmacokinetics and Pharmacodynamics of Cannabinoids

verfasst von: Dr Franjo Grotenhermen

Erschienen in: Clinical Pharmacokinetics | Ausgabe 4/2003

Einloggen, um Zugang zu erhalten

Abstract

Δ9-Tetrahydrocannabinol (THC) is the main source of the pharmacological effects caused by the consumption of cannabis, both the marijuana-like action and the medicinal benefits of the plant. However, its acid metabolite THC-COOH, the non-psychotropic cannabidiol (CBD), several cannabinoid analogues and newly discovered modulators of the endogenous cannabinoid system are also promising candidates for clinical research and therapeutic uses. Cannabinoids exert many effects through activation of G-protein-coupled cannabinoid receptors in the brain and peripheral tissues. Additionally, there is evidence for nonreceptor-dependent mechanisms.
Natural cannabis products and single cannabinoids are usually inhaled or taken orally; the rectal route, sublingual administration, transdermal delivery, eye drops and aerosols have only been used in a few studies and are of little relevance in practice today. The pharmacokinetics of THC vary as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes, psychotropic effects start within seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12 hours, depending on dose and specific effect.
At doses exceeding the psychotropic threshold, ingestion of cannabis usually causes enhanced well-being and relaxation with an intensification of ordinary sensory experiences. The most important acute adverse effects caused by overdosing are anxiety and panic attacks, and with regard to somatic effects increased heart rate and changes in blood pressure. Regular use of cannabis may lead to dependency and to a mild withdrawal syndrome. The existence and the intensity of possible long-term adverse effects on psyche and cognition, immune system, fertility and pregnancy remain controversial. They are reported to be low in humans and do not preclude legitimate therapeutic use of cannabis-based drugs.
Properties of cannabis that might be of therapeutic use include analgesia, muscle relaxation, immunosuppression, sedation, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and induction of apoptosis in cancer cells.
Fußnoten
1
Use of tradenames is for product identification only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Loewe S. Cannabiswirkstoffe und Pharmakologie der Cannabinole. Archiv Experimentelle Pathologie Pharmakologie 1950; 211: 175–93 Loewe S. Cannabiswirkstoffe und Pharmakologie der Cannabinole. Archiv Experimentelle Pathologie Pharmakologie 1950; 211: 175–93
2.
Zurück zum Zitat Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38(2): 151–78PubMed Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38(2): 151–78PubMed
3.
Zurück zum Zitat Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1–20PubMed Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986; 38: 1–20PubMed
4.
Zurück zum Zitat Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of the active constituent of hashish. J Am Chem Soc 1964; 86: 1646–7CrossRef Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of the active constituent of hashish. J Am Chem Soc 1964; 86: 1646–7CrossRef
5.
Zurück zum Zitat Devane WA, Dysarz III FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34(5): 605–13PubMed Devane WA, Dysarz III FA, Johnson MR, et al. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34(5): 605–13PubMed
6.
Zurück zum Zitat Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258(5090): 1946–9PubMedCrossRef Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258(5090): 1946–9PubMedCrossRef
7.
Zurück zum Zitat Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986; 38: 75–149PubMed Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986; 38: 75–149PubMed
8.
Zurück zum Zitat Pate D. Taxonomy of cannabinoids. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 15–26 Pate D. Taxonomy of cannabinoids. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 15–26
9.
Zurück zum Zitat ElSohly MA. Chemical constituents of cannabis. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 27–36 ElSohly MA. Chemical constituents of cannabis. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 27–36
10.
Zurück zum Zitat Field BI, Arndt RR. Cannabinoid compounds in South African Cannabis sativa L. J Pharm Pharmacol 1980; 32(1): 21–4PubMedCrossRef Field BI, Arndt RR. Cannabinoid compounds in South African Cannabis sativa L. J Pharm Pharmacol 1980; 32(1): 21–4PubMedCrossRef
11.
Zurück zum Zitat Pitts JE, Neal JD, Gough TA. Some features of Cannabis plants grown in the United Kingdom from seeds of known origin. J Pharm Pharmacol 1992; 44(12): 947–51PubMedCrossRef Pitts JE, Neal JD, Gough TA. Some features of Cannabis plants grown in the United Kingdom from seeds of known origin. J Pharm Pharmacol 1992; 44(12): 947–51PubMedCrossRef
12.
Zurück zum Zitat Rowan MG, Fairbairn JW. Cannabinoid patterns in seedlings of Cannabis sativa L. and their use in the determination of chemical race. J Pharm Pharmacol 1977; 29(8): 491–4PubMedCrossRef Rowan MG, Fairbairn JW. Cannabinoid patterns in seedlings of Cannabis sativa L. and their use in the determination of chemical race. J Pharm Pharmacol 1977; 29(8): 491–4PubMedCrossRef
13.
Zurück zum Zitat Harvey DJ. Characterization of the butyl homologues of deltal tetrahydrocannabinol, cannabinol and cannabidiol in samples of cannabis by combined gas chromatography and mass spectrometry. J Pharm Pharmacol 1976; 28(4): 280–5PubMedCrossRef Harvey DJ. Characterization of the butyl homologues of deltal tetrahydrocannabinol, cannabinol and cannabidiol in samples of cannabis by combined gas chromatography and mass spectrometry. J Pharm Pharmacol 1976; 28(4): 280–5PubMedCrossRef
14.
Zurück zum Zitat Vree TB, Breimer DD, van Ginneken CA, et al. Identification in hashish of tetrahydrocannabinol, cannabidiol and cannabinol analogues with a methyl side-chain. J Pharm Pharmacol 1972; 24(1): 7–12PubMedCrossRef Vree TB, Breimer DD, van Ginneken CA, et al. Identification in hashish of tetrahydrocannabinol, cannabidiol and cannabinol analogues with a methyl side-chain. J Pharm Pharmacol 1972; 24(1): 7–12PubMedCrossRef
15.
Zurück zum Zitat ElSohly MA, Ross SA, Mehmedic Z, et al. Potency trends of Δ9-THC and other cannabinoids in confiscated marijuana from 1980–1997. J Forensic Sci 2000; 45(1): 24–30PubMed ElSohly MA, Ross SA, Mehmedic Z, et al. Potency trends of Δ9-THC and other cannabinoids in confiscated marijuana from 1980–1997. J Forensic Sci 2000; 45(1): 24–30PubMed
16.
Zurück zum Zitat Brenneisen R. Psychotrope drogen: II. Bestimmung der Cannabinoide in Cannabis sativa L. und in Cannabisprodukten mittels Hochdruckflüssigkeitschromatographie (HPLC). Pharm Acta Helv 1984; 59: 247–59PubMed Brenneisen R. Psychotrope drogen: II. Bestimmung der Cannabinoide in Cannabis sativa L. und in Cannabisprodukten mittels Hochdruckflüssigkeitschromatographie (HPLC). Pharm Acta Helv 1984; 59: 247–59PubMed
17.
Zurück zum Zitat Baker PB, Taylor BJ, Gough TA. The tetrahydrocannabinol and tetrahydrocannabinolic acid content of cannabis products. J Pharm Pharmacol 1981; 33(6): 369–72PubMedCrossRef Baker PB, Taylor BJ, Gough TA. The tetrahydrocannabinol and tetrahydrocannabinolic acid content of cannabis products. J Pharm Pharmacol 1981; 33(6): 369–72PubMedCrossRef
18.
Zurück zum Zitat Garrett ER, Hunt CA. Physiochemical properties, solubility, and protein binding of Δ9-tetrahydrocannabinol. J Pharm Sci 1974; 63(7): 1056–64PubMedCrossRef Garrett ER, Hunt CA. Physiochemical properties, solubility, and protein binding of Δ9-tetrahydrocannabinol. J Pharm Sci 1974; 63(7): 1056–64PubMedCrossRef
19.
Zurück zum Zitat Mechoulam R. Chemistry of cannabis. Handbook Exp Pharmacol 1981; 53: 119–34 Mechoulam R. Chemistry of cannabis. Handbook Exp Pharmacol 1981; 53: 119–34
20.
Zurück zum Zitat Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 1990; 255(2): 624–30PubMed Thomas BF, Compton DR, Martin BR. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 1990; 255(2): 624–30PubMed
21.
Zurück zum Zitat Johnson JR, Jennison TA, Peat MA, et al. Stability of delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol 1984; 8(5): 202–4PubMed Johnson JR, Jennison TA, Peat MA, et al. Stability of delta 9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC in blood and plasma. J Anal Toxicol 1984; 8(5): 202–4PubMed
22.
Zurück zum Zitat NN Monographs: Dronabinol capsules 2.5/5 or 10mg (NRF 22.7.); oily dronabinol drops 2.5% (NRF 22.8). In: Bundesvereinigung Deutscher Apothekerverbände, editor. Neues Rezepturformularium (NRF), Loose-Leaf Collection of 2001. Eschborn, Germany: Govi-Verlag Pharmazeutischer Verlag / Stuttgart, Germany: Deutscher Apotheker-Verlag, 2001 NN Monographs: Dronabinol capsules 2.5/5 or 10mg (NRF 22.7.); oily dronabinol drops 2.5% (NRF 22.8). In: Bundesvereinigung Deutscher Apothekerverbände, editor. Neues Rezepturformularium (NRF), Loose-Leaf Collection of 2001. Eschborn, Germany: Govi-Verlag Pharmazeutischer Verlag / Stuttgart, Germany: Deutscher Apotheker-Verlag, 2001
23.
Zurück zum Zitat Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 1971; 8(4): 391–402PubMed Agurell S, Leander K. Stability, transfer and absorption of cannabinoid constituents of cannabis (hashish) during smoking. Acta Pharm Suec 1971; 8(4): 391–402PubMed
24.
Zurück zum Zitat Fairbairn JW, Liebmann JA, Rowan MG. The stability of cannabis and its preparations on storage. J Pharm Pharmacol 1976; 28: 1–7PubMedCrossRef Fairbairn JW, Liebmann JA, Rowan MG. The stability of cannabis and its preparations on storage. J Pharm Pharmacol 1976; 28: 1–7PubMedCrossRef
25.
Zurück zum Zitat Brenneisen R, Egli A, Elsohly MA, et al. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996; 34(10): 446–52PubMed Brenneisen R, Egli A, Elsohly MA, et al. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996; 34(10): 446–52PubMed
26.
Zurück zum Zitat Stinchcomb A, Challapalli P, Harris K, et al. Optimization of in vitro experimental conditions for measuring the percutaneous absorption of Δ9-THC, cannabidiol, and WIN55,212-2 [abstract]. 2001 Symposium on the Cannabinoids. Burlington (VT): International Cannabinoid Research Society, 2001: 161 Stinchcomb A, Challapalli P, Harris K, et al. Optimization of in vitro experimental conditions for measuring the percutaneous absorption of Δ9-THC, cannabidiol, and WIN55,212-2 [abstract]. 2001 Symposium on the Cannabinoids. Burlington (VT): International Cannabinoid Research Society, 2001: 161
27.
Zurück zum Zitat Guy GW, Flint ME. A phase one study of sublingual Cannabis based medicinal extract. 2000 Symposium on the Cannabinoids. Burlington (VT): International Cannabinoid Research Society: 2000, 115 Guy GW, Flint ME. A phase one study of sublingual Cannabis based medicinal extract. 2000 Symposium on the Cannabinoids. Burlington (VT): International Cannabinoid Research Society: 2000, 115
28.
Zurück zum Zitat Merritt JC, Olsen JL, Armstrong JR, et al. Topical delta 9-tet-rahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol 1981; 33(1): 40–1PubMedCrossRef Merritt JC, Olsen JL, Armstrong JR, et al. Topical delta 9-tet-rahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol 1981; 33(1): 40–1PubMedCrossRef
29.
Zurück zum Zitat Lichtman AH, Peart J, Poklis JL, et al. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol 2000; 399(2–3): 141–9PubMedCrossRef Lichtman AH, Peart J, Poklis JL, et al. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur J Pharmacol 2000; 399(2–3): 141–9PubMedCrossRef
30.
Zurück zum Zitat Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 1976; 31(6): 720–3PubMedCrossRef Williams SJ, Hartley JP, Graham JD. Bronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients. Thorax 1976; 31(6): 720–3PubMedCrossRef
31.
Zurück zum Zitat Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol, in men and women. Clin Pharmacol Ther 1983; 34(3): 352–63PubMedCrossRef Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol, in men and women. Clin Pharmacol Ther 1983; 34(3): 352–63PubMedCrossRef
32.
Zurück zum Zitat Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980; 215(1): 35–44PubMed Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980; 215(1): 35–44PubMed
33.
Zurück zum Zitat Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992; 16(4): 228–35PubMed Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992; 16(4): 228–35PubMed
34.
Zurück zum Zitat Brenneisen R. Pharmakokinetik. In: Grotenhermen F, editor. Cannabis und Cannabinoide. Pharmakologie, Toxikologie und Therapeutisches Potenzial. Göttingen: Hans Huber Verlag, 2001: 87–92 Brenneisen R. Pharmakokinetik. In: Grotenhermen F, editor. Cannabis und Cannabinoide. Pharmakologie, Toxikologie und Therapeutisches Potenzial. Göttingen: Hans Huber Verlag, 2001: 87–92
35.
Zurück zum Zitat Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids: I. absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992; 16(5): 276–82PubMed Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids: I. absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol 1992; 16(5): 276–82PubMed
36.
Zurück zum Zitat Chiang CW, Barnett G. Marijuana effect and delta-9-tetrahy-drocannabinol plasma level. Clin Pharmacol Ther 1984; 36(2): 234–8PubMedCrossRef Chiang CW, Barnett G. Marijuana effect and delta-9-tetrahy-drocannabinol plasma level. Clin Pharmacol Ther 1984; 36(2): 234–8PubMedCrossRef
37.
Zurück zum Zitat Hollister LE, Gillespie HK, Ohlsson A, et al. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 1981; 21 (8–9 Suppl.): 171S–7SPubMed Hollister LE, Gillespie HK, Ohlsson A, et al. Do plasma concentrations of delta 9-tetrahydrocannabinol reflect the degree of intoxication? J Clin Pharmacol 1981; 21 (8–9 Suppl.): 171S–7SPubMed
38.
Zurück zum Zitat Lindgren JE, Ohlsson A, Agurell S, et al. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 1981; 74(3): 208–12PubMedCrossRef Lindgren JE, Ohlsson A, Agurell S, et al. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 1981; 74(3): 208–12PubMedCrossRef
39.
Zurück zum Zitat Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980; 28(3): 409–16PubMedCrossRef Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980; 28(3): 409–16PubMedCrossRef
40.
Zurück zum Zitat Perez-Reyes M, Di Guiseppi S, Davis KH, et al. Comparison of effects of marihuana cigarettes to three different potencies. Clin Pharmacol Ther 1982; 31(5): 617–24PubMedCrossRef Perez-Reyes M, Di Guiseppi S, Davis KH, et al. Comparison of effects of marihuana cigarettes to three different potencies. Clin Pharmacol Ther 1982; 31(5): 617–24PubMedCrossRef
41.
Zurück zum Zitat Sporkert F, Pragst F, Ploner CJ, et al. Pharmacokinetic investigation of delta-9-tetrahydrocannabinol and its metabolites after single administration of 10mg Marinol in attendance of a psychiatric study with 17 volunteers. Poster at the 39th Annual International Meeting, International Association of Forensic Toxicologists; 2001 Aug 26–30; Prague, Czech Republic Sporkert F, Pragst F, Ploner CJ, et al. Pharmacokinetic investigation of delta-9-tetrahydrocannabinol and its metabolites after single administration of 10mg Marinol in attendance of a psychiatric study with 17 volunteers. Poster at the 39th Annual International Meeting, International Association of Forensic Toxicologists; 2001 Aug 26–30; Prague, Czech Republic
42.
Zurück zum Zitat Ohlsson A, Lindgren JE, Wahlen A, et al. Single dose kinetics of deuterium labelled Δ1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 1982; 9(1): 6–10PubMedCrossRef Ohlsson A, Lindgren JE, Wahlen A, et al. Single dose kinetics of deuterium labelled Δ1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 1982; 9(1): 6–10PubMedCrossRef
43.
Zurück zum Zitat Davis KH, McDaniell JA, Cadwell LW, et al. Some smoking characteristics of marijuana cigarettes. In: Agurell S, Dewey WL, Willette RE, editors. The cannabinoids: chemical, pharmacologic and therapeutic aspects. New York: Academic Press, 1984: 245–61 Davis KH, McDaniell JA, Cadwell LW, et al. Some smoking characteristics of marijuana cigarettes. In: Agurell S, Dewey WL, Willette RE, editors. The cannabinoids: chemical, pharmacologic and therapeutic aspects. New York: Academic Press, 1984: 245–61
44.
Zurück zum Zitat Timpone JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 1997; 13(4): 305–15PubMedCrossRef Timpone JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Res Hum Retroviruses 1997; 13(4): 305–15PubMedCrossRef
45.
Zurück zum Zitat Law B, Mason PA, Moffat AC, et al. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 1984; 36(5): 289–94PubMedCrossRef Law B, Mason PA, Moffat AC, et al. Forensic aspects of the metabolism and excretion of cannabinoids following oral ingestion of cannabis resin. J Pharm Pharmacol 1984; 36(5): 289–94PubMedCrossRef
46.
Zurück zum Zitat Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9-tet-rahydrocannabinol in cancer patients. Cancer Treat Rep 1984; 68(12): 1427–31PubMed Frytak S, Moertel CG, Rubin J. Metabolic studies of delta-9-tet-rahydrocannabinol in cancer patients. Cancer Treat Rep 1984; 68(12): 1427–31PubMed
47.
Zurück zum Zitat Harvey DJ. Metabolism and pharmacokinetics of the cannabinoids. In: Watson RR, editor. Biochemistry and physiology of substance abuse. Vol III. Boca Raton (FL): CRC Press, 1991: 279–365 Harvey DJ. Metabolism and pharmacokinetics of the cannabinoids. In: Watson RR, editor. Biochemistry and physiology of substance abuse. Vol III. Boca Raton (FL): CRC Press, 1991: 279–365
48.
Zurück zum Zitat Lemberger L, Weiss JL, Watanabe AM, et al. Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration. N Engl J Med 1972; 286(13): 685–8PubMedCrossRef Lemberger L, Weiss JL, Watanabe AM, et al. Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration. N Engl J Med 1972; 286(13): 685–8PubMedCrossRef
49.
Zurück zum Zitat Chiang CW, Barnett G, Brine D. Systemic absorption of delta 9-tetrahydrocannabinol after ophthalmic administration to the rabbit. J Pharm Sci 1983; 72(2): 136–8PubMedCrossRef Chiang CW, Barnett G, Brine D. Systemic absorption of delta 9-tetrahydrocannabinol after ophthalmic administration to the rabbit. J Pharm Sci 1983; 72(2): 136–8PubMedCrossRef
50.
Zurück zum Zitat ElSohly MA, Stanford DF, Harland EC, et al. Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. J Pharm Sci 1991; 80(10): 942–5PubMedCrossRef ElSohly MA, Stanford DF, Harland EC, et al. Rectal bioavailability of delta-9-tetrahydrocannabinol from the hemisuccinate ester in monkeys. J Pharm Sci 1991; 80(10): 942–5PubMedCrossRef
51.
Zurück zum Zitat Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts in chronic pain: (5) cognitive function and blood cannabinoid levels. 2001 Congress on Cannabis and the Cannabinoids. Cologne, Germany: International Association for Cannabis as Medicine; 28 Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts in chronic pain: (5) cognitive function and blood cannabinoid levels. 2001 Congress on Cannabis and the Cannabinoids. Cologne, Germany: International Association for Cannabis as Medicine; 28
52.
Zurück zum Zitat Touitou E, Fabin B, Dany S, et al. Transdermal delivery of tetrahydrocannabinol. Int J Pharm 1988; 43: 9–15CrossRef Touitou E, Fabin B, Dany S, et al. Transdermal delivery of tetrahydrocannabinol. Int J Pharm 1988; 43: 9–15CrossRef
53.
Zurück zum Zitat Leuschner JT, Harvey DJ, Bullingham RE, et al. Pharmacokinetics of delta 9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses. Drug Metab Dispos 1986; 14(2): 230–8PubMed Leuschner JT, Harvey DJ, Bullingham RE, et al. Pharmacokinetics of delta 9-tetrahydrocannabinol in rabbits following single or multiple intravenous doses. Drug Metab Dispos 1986; 14(2): 230–8PubMed
54.
Zurück zum Zitat Widman M, Agurell S, Ehrnebo M, et al. Binding of (+)- and (−)-Δ1- tetrahydrocannabinols and (−)-7-hydroxy-Δ1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol 1974; 26(11): 914–6PubMedCrossRef Widman M, Agurell S, Ehrnebo M, et al. Binding of (+)- and (−)-Δ1- tetrahydrocannabinols and (−)-7-hydroxy-Δ1-tetrahydrocannabinol to blood cells and plasma proteins in man. J Pharm Pharmacol 1974; 26(11): 914–6PubMedCrossRef
55.
Zurück zum Zitat Fehr KO, Kalant H. Fate of 14C-delta1-THC in rat plasma after intravenous injection and smoking. Eur J Pharmacol 1974; 25(1): 1–8PubMedCrossRef Fehr KO, Kalant H. Fate of 14C-delta1-THC in rat plasma after intravenous injection and smoking. Eur J Pharmacol 1974; 25(1): 1–8PubMedCrossRef
56.
Zurück zum Zitat Wahlqvist M, Nilsson IM, Sandberg F, et al. Binding of delta1-tetrahydrocannabinol to human plasma proteins. Biochem Pharmacol 1970; 19(9): 2579–84PubMedCrossRef Wahlqvist M, Nilsson IM, Sandberg F, et al. Binding of delta1-tetrahydrocannabinol to human plasma proteins. Biochem Pharmacol 1970; 19(9): 2579–84PubMedCrossRef
57.
Zurück zum Zitat Lemberger L, Tamarkin NR, Axelrod J, et al. Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 1971; 173(991): 72–4PubMedCrossRef Lemberger L, Tamarkin NR, Axelrod J, et al. Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 1971; 173(991): 72–4PubMedCrossRef
58.
Zurück zum Zitat Barnett G, Chiang CW, Perez-Reyes M, et al. Kinetic study of smoking marijuana. J Pharmacokinet Biopharm 1982; 10(5): 495–506PubMed Barnett G, Chiang CW, Perez-Reyes M, et al. Kinetic study of smoking marijuana. J Pharmacokinet Biopharm 1982; 10(5): 495–506PubMed
59.
Zurück zum Zitat Brewster ME, Pop E, Foltz RL, et al. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int J Clin Pharmacol Ther 1997; 35(9): 361–5PubMed Brewster ME, Pop E, Foltz RL, et al. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers. Int J Clin Pharmacol Ther 1997; 35(9): 361–5PubMed
60.
Zurück zum Zitat Sticht G, Käferstein H. Grundbegriffe, toxikokinetik und toxikodynamik. In: Berghaus G, Krüger HP, editors. Cannabis im Straßenverkehr. Stuttgart: Gustav Fischer, 1998: 1–11 Sticht G, Käferstein H. Grundbegriffe, toxikokinetik und toxikodynamik. In: Berghaus G, Krüger HP, editors. Cannabis im Straßenverkehr. Stuttgart: Gustav Fischer, 1998: 1–11
61.
Zurück zum Zitat Ryrfeldt A, Ramsay CH, Nilsson IM, et al. Whole-body auto radiography of Δ1-tetrahydrocannabinol and Δ1 (6)-tetrahydrocannabinol in mouse: pharmacokinetic aspects of Δ1-tetrahydrocannabinol and its metabolites. Acta Pharm Suec 1973; 10(1): 13–28PubMed Ryrfeldt A, Ramsay CH, Nilsson IM, et al. Whole-body auto radiography of Δ1-tetrahydrocannabinol and Δ1 (6)-tetrahydrocannabinol in mouse: pharmacokinetic aspects of Δ1-tetrahydrocannabinol and its metabolites. Acta Pharm Suec 1973; 10(1): 13–28PubMed
62.
Zurück zum Zitat Ho BT, Fritchie GE, Kralik PM, et al. Distribution of tritiated-1 delta 9-tetrahydrocannabinol in rat tissues after inhalation. J Pharm Pharmacol 1970; 22(7): 538–9PubMedCrossRef Ho BT, Fritchie GE, Kralik PM, et al. Distribution of tritiated-1 delta 9-tetrahydrocannabinol in rat tissues after inhalation. J Pharm Pharmacol 1970; 22(7): 538–9PubMedCrossRef
63.
Zurück zum Zitat Gill EW, Jones G. Brain levels of Δ1-tetrahydrocannabinol and its metabolites in mice: correlation with behaviour, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide. Biochem Pharmacol 1972; 21(16): 2237–48PubMedCrossRef Gill EW, Jones G. Brain levels of Δ1-tetrahydrocannabinol and its metabolites in mice: correlation with behaviour, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide. Biochem Pharmacol 1972; 21(16): 2237–48PubMedCrossRef
64.
Zurück zum Zitat Chiang CN, Rapaka RS. Pharmacokinetics and disposition of cannabinoids. NIDA Res Monogr 1987; 79: 173–88PubMed Chiang CN, Rapaka RS. Pharmacokinetics and disposition of cannabinoids. NIDA Res Monogr 1987; 79: 173–88PubMed
65.
Zurück zum Zitat Perez-Reyes M, Simmons J, Brine D, et al. Rate of penetration of Δ9-tetrahydrocannabinol and 11-hydroxy-Δ9-tetrahydrocannabinol to the brain of mice. In: Nahas GG, editor. Marihuana: chemistry, biochemistry, and cellular effects. New York: Springer, 1976: 179–85 Perez-Reyes M, Simmons J, Brine D, et al. Rate of penetration of Δ9-tetrahydrocannabinol and 11-hydroxy-Δ9-tetrahydrocannabinol to the brain of mice. In: Nahas GG, editor. Marihuana: chemistry, biochemistry, and cellular effects. New York: Springer, 1976: 179–85
66.
Zurück zum Zitat Agurell S, Nilsson IM, Ohlsson A, et al. On the metabolism of tritium-labelled, 1-tetrahydrocannabinol in the rabbit. Biochem Pharmacol 1970; 19(4): 1333–9PubMedCrossRef Agurell S, Nilsson IM, Ohlsson A, et al. On the metabolism of tritium-labelled, 1-tetrahydrocannabinol in the rabbit. Biochem Pharmacol 1970; 19(4): 1333–9PubMedCrossRef
67.
Zurück zum Zitat Johansson E, Noren K, Sjovall J, et al. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 1989; 3(1): 35–8PubMedCrossRef Johansson E, Noren K, Sjovall J, et al. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr 1989; 3(1): 35–8PubMedCrossRef
68.
Zurück zum Zitat Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science 1973; 179(71): 391–3PubMedCrossRef Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science 1973; 179(71): 391–3PubMedCrossRef
69.
Zurück zum Zitat Harvey DJ, Leuschner JT, Paton WD. Gas chromatographic and mass spectrometric studies on the metabolism and phar-macokinetics of delta 1-tetrahydrocannabinol in the rabbit. J Chromatogr 1982; 239: 243–50PubMedCrossRef Harvey DJ, Leuschner JT, Paton WD. Gas chromatographic and mass spectrometric studies on the metabolism and phar-macokinetics of delta 1-tetrahydrocannabinol in the rabbit. J Chromatogr 1982; 239: 243–50PubMedCrossRef
70.
Zurück zum Zitat Haggerty GC, Deskin R, Kurtz PJ, et al. The pharmacological activity of the fatty acid conjugate 11-palmitoyloxy-delta 9-tetrahydrocannabinol. Toxicol Appl Pharmacol 1986; 84(3): 599–606PubMedCrossRef Haggerty GC, Deskin R, Kurtz PJ, et al. The pharmacological activity of the fatty acid conjugate 11-palmitoyloxy-delta 9-tetrahydrocannabinol. Toxicol Appl Pharmacol 1986; 84(3): 599–606PubMedCrossRef
71.
Zurück zum Zitat Leighty EG, Fentiman Jr AF, Foltz RL. Long-retained metabolites of Δ9- and Δ8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976; 14(1): 13–28PubMed Leighty EG, Fentiman Jr AF, Foltz RL. Long-retained metabolites of Δ9- and Δ8-tetrahydrocannabinols identified as novel fatty acid conjugates. Res Commun Chem Pathol Pharmacol 1976; 14(1): 13–28PubMed
72.
Zurück zum Zitat Blackard C, Tennes K. Human placental transfer of can nabinoids [letter]. N Engl J Med 1984; 311: 797PubMed Blackard C, Tennes K. Human placental transfer of can nabinoids [letter]. N Engl J Med 1984; 311: 797PubMed
73.
Zurück zum Zitat Abrams RM, Cook CE, Davis KH, et al. Plasma delta-9-tetra-hydrocannabinol in pregnant sheep and fetus after inhalation of smoke from a marijuana cigarette. Alcohol Drug Res 1985–1986; 6: 361–9PubMed Abrams RM, Cook CE, Davis KH, et al. Plasma delta-9-tetra-hydrocannabinol in pregnant sheep and fetus after inhalation of smoke from a marijuana cigarette. Alcohol Drug Res 1985–1986; 6: 361–9PubMed
74.
Zurück zum Zitat Bailey JR, Cunny HC, Paule MG, et al. Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 1987; 90: 315–21PubMedCrossRef Bailey JR, Cunny HC, Paule MG, et al. Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 1987; 90: 315–21PubMedCrossRef
75.
Zurück zum Zitat Hutchings DE, Martin BR, Gamagaris Z, et al. Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci 1989; 44(11): 697–701PubMedCrossRef Hutchings DE, Martin BR, Gamagaris Z, et al. Plasma concentrations of delta-9-tetrahydrocannabinol in dams and fetuses following acute or multiple prenatal dosing in rats. Life Sci 1989; 44(11): 697–701PubMedCrossRef
76.
Zurück zum Zitat Martin BR, Dewey WL, Harris LS, et al. 3H-delta 9-tetrahydrocannabinol distribution in pregnant dogs and their fetuses. Res Commun Chem Pathol Pharmacol 1977; 17: 457–70PubMed Martin BR, Dewey WL, Harris LS, et al. 3H-delta 9-tetrahydrocannabinol distribution in pregnant dogs and their fetuses. Res Commun Chem Pathol Pharmacol 1977; 17: 457–70PubMed
77.
Zurück zum Zitat Boskovic R, Klein J, Woodland C, et al. The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: a twin study. Can J Physiol Pharmacol 2001; 79(11): 942–5PubMedCrossRef Boskovic R, Klein J, Woodland C, et al. The role of the placenta in variability of fetal exposure to cocaine and cannabinoids: a twin study. Can J Physiol Pharmacol 2001; 79(11): 942–5PubMedCrossRef
78.
Zurück zum Zitat Chao FC, Green DE, Forrest IS, et al. The passage of 14C-delta 9-tetrahydrocannabinol into the milk of lactating squirrel monkeys. Res Commun Chem Pathol Pharmacol 1976; 15: 303–17PubMed Chao FC, Green DE, Forrest IS, et al. The passage of 14C-delta 9-tetrahydrocannabinol into the milk of lactating squirrel monkeys. Res Commun Chem Pathol Pharmacol 1976; 15: 303–17PubMed
79.
Zurück zum Zitat Perez-Reyes M, Wall ME. Presence of delta 9-tetrahydrocannabinol in human milk. N Engl J Med 1982; 307: 819–20PubMedCrossRef Perez-Reyes M, Wall ME. Presence of delta 9-tetrahydrocannabinol in human milk. N Engl J Med 1982; 307: 819–20PubMedCrossRef
80.
Zurück zum Zitat Matsunaga T, Iwawaki Y, Watanabe K, et al. Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci 1995; 56(23–24): 2089–95PubMedCrossRef Matsunaga T, Iwawaki Y, Watanabe K, et al. Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci 1995; 56(23–24): 2089–95PubMedCrossRef
81.
Zurück zum Zitat Narimatsu S, Watanabe K, Matsunaga T, et al. Cytochrome P-450 isozymes involved in the oxidative metabolism of delta 9-tetrahydrocannabinol by liver microsomes of adult female rats. Drug Metab Dispos 1992; 20(1): 79–83PubMed Narimatsu S, Watanabe K, Matsunaga T, et al. Cytochrome P-450 isozymes involved in the oxidative metabolism of delta 9-tetrahydrocannabinol by liver microsomes of adult female rats. Drug Metab Dispos 1992; 20(1): 79–83PubMed
82.
Zurück zum Zitat Watanabe K, Matsunaga T, Yamamoto I, et al. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 1995; 18(8): 1138–41PubMedCrossRef Watanabe K, Matsunaga T, Yamamoto I, et al. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 1995; 18(8): 1138–41PubMedCrossRef
83.
Zurück zum Zitat Alozie SO, Martin BR, Harris LS, et al. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain. Pharmacol Biochem Behav 1980; 12(2): 217–21PubMedCrossRef Alozie SO, Martin BR, Harris LS, et al. 3H-delta 9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution in rat brain. Pharmacol Biochem Behav 1980; 12(2): 217–21PubMedCrossRef
84.
Zurück zum Zitat Borys HK, Karler R. Cannabidiol and delta 9-tetrahydrocannabinol metabolism: in vitro comparison of mouse and rat liver crude microsome preparations. Biochem Pharmacol 1979; 28(9): 1553–9PubMedCrossRef Borys HK, Karler R. Cannabidiol and delta 9-tetrahydrocannabinol metabolism: in vitro comparison of mouse and rat liver crude microsome preparations. Biochem Pharmacol 1979; 28(9): 1553–9PubMedCrossRef
85.
Zurück zum Zitat Harvey DJ, Brown NK. Comparative in vitro metabolism of the cannabinoids. Pharmacol Biochem Behav 1991; 40(3): 533–40PubMedCrossRef Harvey DJ, Brown NK. Comparative in vitro metabolism of the cannabinoids. Pharmacol Biochem Behav 1991; 40(3): 533–40PubMedCrossRef
86.
Zurück zum Zitat Grotenhermen F. Review of unwanted actions of cannabis and THC. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 233–48 Grotenhermen F. Review of unwanted actions of cannabis and THC. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 233–48
87.
Zurück zum Zitat Harvey DJ, Paton WDM. Examination of the metabolites of Δ1-tetrahydrocannabinol in mouse, liver, heart and lung by combined gas chromatography and mass spectrometry. In: Nahas GG, editor. Marihuana: chemistry, biochemistry and cellular effects. New York: Springer-Verlag, 1976: 93–107 Harvey DJ, Paton WDM. Examination of the metabolites of Δ1-tetrahydrocannabinol in mouse, liver, heart and lung by combined gas chromatography and mass spectrometry. In: Nahas GG, editor. Marihuana: chemistry, biochemistry and cellular effects. New York: Springer-Verlag, 1976: 93–107
88.
Zurück zum Zitat Nakazawa K, Costa E. Metabolism of delta 9-tetrahydrocannabinol by lung and liver homogenates of rats treated with methylcholanthrene. Nature 1971; 234(5323): 48–9PubMedCrossRef Nakazawa K, Costa E. Metabolism of delta 9-tetrahydrocannabinol by lung and liver homogenates of rats treated with methylcholanthrene. Nature 1971; 234(5323): 48–9PubMedCrossRef
89.
Zurück zum Zitat Widman M, Nordqvist M, Dollery CT, et al. Metabolism of delta1-tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver metabolism. J Pharm Pharmacol 1975; 27(11): 842–8PubMedCrossRef Widman M, Nordqvist M, Dollery CT, et al. Metabolism of delta1-tetrahydrocannabinol by the isolated perfused dog lung. Comparison with in vitro liver metabolism. J Pharm Pharmacol 1975; 27(11): 842–8PubMedCrossRef
90.
Zurück zum Zitat Wall ME. The in vivo and in vitro metabolism of tetrahydrocannabinol. Ann N Y Acad Sci 1971; 191: 23–9CrossRef Wall ME. The in vivo and in vitro metabolism of tetrahydrocannabinol. Ann N Y Acad Sci 1971; 191: 23–9CrossRef
91.
Zurück zum Zitat Widman M, Halldin M, Martin B. In vitro metabolism of tetrahydrocannabinol by rhesus monkey liver and human liver. Adv Biosci 1978; 22-23: 101–3PubMed Widman M, Halldin M, Martin B. In vitro metabolism of tetrahydrocannabinol by rhesus monkey liver and human liver. Adv Biosci 1978; 22-23: 101–3PubMed
92.
Zurück zum Zitat Leighty EG. Metabolism and distribution of cannabinoids in rats after different methods of administration. Biochem Pharmacol 1973; 22(13): 1613–21PubMedCrossRef Leighty EG. Metabolism and distribution of cannabinoids in rats after different methods of administration. Biochem Pharmacol 1973; 22(13): 1613–21PubMedCrossRef
93.
Zurück zum Zitat Johansson E, Halldin MM, Agurell S, et al. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 1989; 37(3): 273–7PubMedCrossRef Johansson E, Halldin MM, Agurell S, et al. Terminal elimination plasma half-life of delta 1-tetrahydrocannabinol (delta 1-THC) in heavy users of marijuana. Eur J Clin Pharmacol 1989; 37(3): 273–7PubMedCrossRef
94.
Zurück zum Zitat Schwartz RH, Hayden GF, Riddile M. Laboratory detection of marijuana use: experience with a photometric immunoassay to measure urinary cannabinoids. Am J Dis Child 1985; 139(11): 1093–6PubMed Schwartz RH, Hayden GF, Riddile M. Laboratory detection of marijuana use: experience with a photometric immunoassay to measure urinary cannabinoids. Am J Dis Child 1985; 139(11): 1093–6PubMed
95.
Zurück zum Zitat Ellis Jr GM, Mann MA, Judson BA, et al. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 1985; 38(5): 572–8PubMedCrossRef Ellis Jr GM, Mann MA, Judson BA, et al. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther 1985; 38(5): 572–8PubMedCrossRef
96.
Zurück zum Zitat Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in humans. Ther Drug Monit 1998; 20(5): 570–6PubMedCrossRef Huestis MA, Cone EJ. Urinary excretion half-life of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in humans. Ther Drug Monit 1998; 20(5): 570–6PubMedCrossRef
97.
Zurück zum Zitat Johansson E, Halldin MM. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 1989; 13(4): 218–23PubMed Johansson E, Halldin MM. Urinary excretion half-life of delta 1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. J Anal Toxicol 1989; 13(4): 218–23PubMed
98.
Zurück zum Zitat Halldin MM, Andersson LK, Widman M, et al. Further urinary metabolites of delta 1-tetrahydrocannabinol in man. Arzneimittel Forschung 1982; 32(9): 1135–8PubMed Halldin MM, Andersson LK, Widman M, et al. Further urinary metabolites of delta 1-tetrahydrocannabinol in man. Arzneimittel Forschung 1982; 32(9): 1135–8PubMed
99.
Zurück zum Zitat Halldin MM, Carlsson S, Kanter SL, et al. Urinary metabolites of delta 1-tetrahydrocannabinol in man. Arzneimittel Forschung 1982; 32(7): 764–8PubMed Halldin MM, Carlsson S, Kanter SL, et al. Urinary metabolites of delta 1-tetrahydrocannabinol in man. Arzneimittel Forschung 1982; 32(7): 764–8PubMed
100.
Zurück zum Zitat Williams PL, Moffat AC. Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 1980; 32(7): 445–8PubMedCrossRef Williams PL, Moffat AC. Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 1980; 32(7): 445–8PubMedCrossRef
101.
Zurück zum Zitat Alburges ME, Peat MA. Profiles of delta 9-tetrahydrocannabinol metabolites in urine of marijuana users: preliminary observations by high performance liquid chromatographyradioimmunoassay. J Forensic Sci 1986; 31(2): 695–706PubMed Alburges ME, Peat MA. Profiles of delta 9-tetrahydrocannabinol metabolites in urine of marijuana users: preliminary observations by high performance liquid chromatographyradioimmunoassay. J Forensic Sci 1986; 31(2): 695–706PubMed
102.
Zurück zum Zitat Wall ME, Perez-Reyes M. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 178S–89SPubMed Wall ME, Perez-Reyes M. The metabolism of delta 9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 178S–89SPubMed
103.
Zurück zum Zitat Manno JE, Manno BR, Kemp PM, et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-Δ9-tetrahydrocannabinol9-carboxylic acid. J Anal Toxicol 2001; 25(7): 538–49PubMed Manno JE, Manno BR, Kemp PM, et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of Δ9-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, and 11-nor-Δ9-tetrahydrocannabinol9-carboxylic acid. J Anal Toxicol 2001; 25(7): 538–49PubMed
104.
Zurück zum Zitat Mikes F, Hofmann A, Waser PG. Identification of (-)-delta 9-6a,10a-trans-tetrahydrocannabinol and two of its metabolites in rats by use of combination gas chromatography-mass spectrometry and mass fragmentography. Biochem Pharmacol 1971; 20(9): 2469–76PubMedCrossRef Mikes F, Hofmann A, Waser PG. Identification of (-)-delta 9-6a,10a-trans-tetrahydrocannabinol and two of its metabolites in rats by use of combination gas chromatography-mass spectrometry and mass fragmentography. Biochem Pharmacol 1971; 20(9): 2469–76PubMedCrossRef
105.
Zurück zum Zitat Harder S, Rietbrock S. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther 1997; 35(4): 155–9PubMed Harder S, Rietbrock S. Concentration-effect relationship of delta-9-tetrahydrocannabiol and prediction of psychotropic effects after smoking marijuana. Int J Clin Pharmacol Ther 1997; 35(4): 155–9PubMed
106.
Zurück zum Zitat Robbe HWJ. Influence of marijuana on driving. Maastricht: Institut for Human Psychopharmacology, University of Limburg, 1994 Robbe HWJ. Influence of marijuana on driving. Maastricht: Institut for Human Psychopharmacology, University of Limburg, 1994
107.
Zurück zum Zitat Barnett G, Licko V, Thompson T. Behavioral pharmacokinetics of marijuana. Psychopharmacology 1985; 85(1): 51–6PubMedCrossRef Barnett G, Licko V, Thompson T. Behavioral pharmacokinetics of marijuana. Psychopharmacology 1985; 85(1): 51–6PubMedCrossRef
108.
Zurück zum Zitat Cocchetto DM, Owens SM, Perez-Reyes M, et al. Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology 1981; 75(2): 158–64PubMedCrossRef Cocchetto DM, Owens SM, Perez-Reyes M, et al. Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology 1981; 75(2): 158–64PubMedCrossRef
109.
Zurück zum Zitat Nyoni EC, Sitaram BR, Taylor DA. Determination of delta 9-tetrahydrocannabinol levels in brain tissue using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1996; 679(1–2): 79–84PubMedCrossRef Nyoni EC, Sitaram BR, Taylor DA. Determination of delta 9-tetrahydrocannabinol levels in brain tissue using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1996; 679(1–2): 79–84PubMedCrossRef
110.
Zurück zum Zitat McIsaac W, Fritchie G, Idanpaan-Heikkila J, et al. Distribution of marihuana in monkey brain and concomitant behavioural effects. Nature 1971; 230(5296): 593–4PubMedCrossRef McIsaac W, Fritchie G, Idanpaan-Heikkila J, et al. Distribution of marihuana in monkey brain and concomitant behavioural effects. Nature 1971; 230(5296): 593–4PubMedCrossRef
111.
Zurück zum Zitat Ohlsson A, Widman M, Carlsson S, et al. Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol Toxicol (Copenh); 1980; 47(4): 308–17CrossRef Ohlsson A, Widman M, Carlsson S, et al. Plasma and brain levels of delta 6-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol Toxicol (Copenh); 1980; 47(4): 308–17CrossRef
112.
Zurück zum Zitat Law B, Moffat AC. The influence of the metabolism and elimination of cannabinoids on forensic analysis and interpretation. In: Harvey DJ, editor. Marijuana’ 84: Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press Limited, 1985: 197–204 Law B, Moffat AC. The influence of the metabolism and elimination of cannabinoids on forensic analysis and interpretation. In: Harvey DJ, editor. Marijuana’ 84: Proceedings of the Oxford Symposium on Cannabis. Oxford: IRL Press Limited, 1985: 197–204
113.
Zurück zum Zitat McBurney LJ, Bobbie BA, Sepp LA. GC/MS and EMIT analyses for delta 9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. J Anal Toxicol 1986; 10(2): 56–64PubMed McBurney LJ, Bobbie BA, Sepp LA. GC/MS and EMIT analyses for delta 9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. J Anal Toxicol 1986; 10(2): 56–64PubMed
114.
Zurück zum Zitat Daldrup TH. Cannabis im Straßenverkehr. Final report commissioned by the Ministry of Economy, Technology and Traffic of North Rhine-Westphalia. Düsseldorf: University of Düsseldorf, 1996 Daldrup TH. Cannabis im Straßenverkehr. Final report commissioned by the Ministry of Economy, Technology and Traffic of North Rhine-Westphalia. Düsseldorf: University of Düsseldorf, 1996
115.
Zurück zum Zitat Hanson V, Buonarati M, Baselt R, et al. Comparison of 3H- and 125I-radioimmunoassay and gas chromatography/mass spectrometry for the determination of Δ9-tetrahydrocannabinol and cannabinoids in blood and serum. J Anal Toxicol 1983; 7: 96–102PubMed Hanson V, Buonarati M, Baselt R, et al. Comparison of 3H- and 125I-radioimmunoassay and gas chromatography/mass spectrometry for the determination of Δ9-tetrahydrocannabinol and cannabinoids in blood and serum. J Anal Toxicol 1983; 7: 96–102PubMed
116.
Zurück zum Zitat Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids: II. models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-te trahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 1992; 16(5): 283–90PubMed Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids: II. models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-te trahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 1992; 16(5): 283–90PubMed
117.
Zurück zum Zitat Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986; 38(1): 21–43PubMed Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986; 38(1): 21–43PubMed
118.
Zurück zum Zitat Ohlsson A, Lindgren JE, Andersson S, et al. Single dose kinetics of cannabidiol in man. In: Agurell S, Dewey WL, Willette R, editors. The cannabinoids: chemical, pharmacologic, and therapeutic aspects. New York: Academic Press, 1984: 219–25 Ohlsson A, Lindgren JE, Andersson S, et al. Single dose kinetics of cannabidiol in man. In: Agurell S, Dewey WL, Willette R, editors. The cannabinoids: chemical, pharmacologic, and therapeutic aspects. New York: Academic Press, 1984: 219–25
119.
Zurück zum Zitat Agurell S, Carlsson S, Lindgren JE, et al. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man: assay of cannabinol and cannabidiol by mass fragmentography. Experientia 1981; 37(10): 1090–2PubMedCrossRef Agurell S, Carlsson S, Lindgren JE, et al. Interactions of delta 1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man: assay of cannabinol and cannabidiol by mass fragmentography. Experientia 1981; 37(10): 1090–2PubMedCrossRef
120.
Zurück zum Zitat Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 1991; 40(3): 701–8PubMedCrossRef Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 1991; 40(3): 701–8PubMedCrossRef
121.
Zurück zum Zitat Harvey DJ, Mechoulam R. Metabolites of cannabidiol identified in human urine. Xenobiotica 1990; 20(3): 303–20PubMedCrossRef Harvey DJ, Mechoulam R. Metabolites of cannabidiol identified in human urine. Xenobiotica 1990; 20(3): 303–20PubMedCrossRef
122.
Zurück zum Zitat Wall ME, Brine DR, Perez-Reyes M. Metabolism of cannabinoids in man. In: Braude MC, Szara S, editors. Pharmacology of marihuana. New York: Raven Press, 1976: 93–113 Wall ME, Brine DR, Perez-Reyes M. Metabolism of cannabinoids in man. In: Braude MC, Szara S, editors. Pharmacology of marihuana. New York: Raven Press, 1976: 93–113
123.
Zurück zum Zitat Lemberger L, Rubin A, Wolen R, et al. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 1982; 9 Suppl. B: 17–23PubMedCrossRef Lemberger L, Rubin A, Wolen R, et al. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 1982; 9 Suppl. B: 17–23PubMedCrossRef
124.
Zurück zum Zitat Rubin A, Lemberger L, Warrick P, et al. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 1977; 22(1): 85–91PubMed Rubin A, Lemberger L, Warrick P, et al. Physiologic disposition of nabilone, a cannabinol derivative, in man. Clin Pharmacol Ther 1977; 22(1): 85–91PubMed
125.
Zurück zum Zitat Sullivan HR, Kau DL, Wood PG. Pharmacokinetics of nabilone, a psychotropically active 9-ketocannabinoid, in the dog. Utilization of quantitative selected ion monitoring and deuterium labeling. Biomed Mass Spectrom 1978; 5(4): 296–301PubMedCrossRef Sullivan HR, Kau DL, Wood PG. Pharmacokinetics of nabilone, a psychotropically active 9-ketocannabinoid, in the dog. Utilization of quantitative selected ion monitoring and deuterium labeling. Biomed Mass Spectrom 1978; 5(4): 296–301PubMedCrossRef
126.
Zurück zum Zitat Sullivan HR, Hanasono GK, Miller WM, et al. Species specificity in the metabolism of nabilone: relationship between toxicity and metabolic routes. Xenobiotica 1987; 17(4): 459–68PubMedCrossRef Sullivan HR, Hanasono GK, Miller WM, et al. Species specificity in the metabolism of nabilone: relationship between toxicity and metabolic routes. Xenobiotica 1987; 17(4): 459–68PubMedCrossRef
127.
Zurück zum Zitat Bornheim LM, Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 1998; 11(10): 1209–16PubMedCrossRef Bornheim LM, Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol 1998; 11(10): 1209–16PubMedCrossRef
128.
Zurück zum Zitat Jaeger W, Benet LZ, Bornheim LM. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 1996; 26(3): 275–84PubMedCrossRef Jaeger W, Benet LZ, Bornheim LM. Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 1996; 26(3): 275–84PubMedCrossRef
129.
Zurück zum Zitat Watanabe K, Arai M, Narimatsu S, et al. Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. Biochem Pharmacol 1987; 36(20): 3371–7PubMedCrossRef Watanabe K, Arai M, Narimatsu S, et al. Self-catalyzed inactivation of cytochrome P-450 during microsomal metabolism of cannabidiol. Biochem Pharmacol 1987; 36(20): 3371–7PubMedCrossRef
130.
Zurück zum Zitat Yamamoto I, Watanabe K, Narimatsu S, et al. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 1995; 27(8): 741–6PubMedCrossRef Yamamoto I, Watanabe K, Narimatsu S, et al. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 1995; 27(8): 741–6PubMedCrossRef
131.
Zurück zum Zitat Bornheim LM, Kim KY, Li J, et al. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 1995; 23(8): 825–31PubMed Bornheim LM, Kim KY, Li J, et al. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab Dispos 1995; 23(8): 825–31PubMed
132.
Zurück zum Zitat Hunt CA, Jones RT, Herning RI, et al. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 1981; 9(3): 245–60PubMed Hunt CA, Jones RT, Herning RI, et al. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 1981; 9(3): 245–60PubMed
133.
Zurück zum Zitat Bornheim LM, Everhart ET, Li J, et al. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol 1994; 48(1): 161–71PubMedCrossRef Bornheim LM, Everhart ET, Li J, et al. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol 1994; 48(1): 161–71PubMedCrossRef
134.
Zurück zum Zitat Watanabe K, Arai M, Narimatsu S, et al. Effect of repeated administration of 11-hydroxy-delta 8-tetrahydrocannabinol, an active metabolite of delta 8-tetrahydrocannabinol, on the hepatic microsomal drug-metabolizing enzyme system of mice. Biochem Pharmacol 1986; 35(11): 1861–5PubMedCrossRef Watanabe K, Arai M, Narimatsu S, et al. Effect of repeated administration of 11-hydroxy-delta 8-tetrahydrocannabinol, an active metabolite of delta 8-tetrahydrocannabinol, on the hepatic microsomal drug-metabolizing enzyme system of mice. Biochem Pharmacol 1986; 35(11): 1861–5PubMedCrossRef
135.
Zurück zum Zitat Costa B, Parolaro D, Colleoni M. Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. Eur J Pharmacol 1996; 313(1–2): 17–24PubMedCrossRef Costa B, Parolaro D, Colleoni M. Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. Eur J Pharmacol 1996; 313(1–2): 17–24PubMedCrossRef
136.
Zurück zum Zitat Hollister LE, Gillespie H. Interactions in man of delta-9-tetra-hydrocannabinol: II. cannabinol and cannabidiol. Clin Pharmacol Ther 1975; 18(1): 80–3PubMed Hollister LE, Gillespie H. Interactions in man of delta-9-tetra-hydrocannabinol: II. cannabinol and cannabidiol. Clin Pharmacol Ther 1975; 18(1): 80–3PubMed
137.
Zurück zum Zitat Zuardi AW, Shirakawa I, Finkelfarb E, et al. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982; 76(3): 245–50PubMedCrossRef Zuardi AW, Shirakawa I, Finkelfarb E, et al. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology 1982; 76(3): 245–50PubMedCrossRef
138.
Zurück zum Zitat Karniol IG, Shirakawa I, Kasinski N, et al. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 1974; 28(1): 172–7PubMedCrossRef Karniol IG, Shirakawa I, Kasinski N, et al. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 1974; 28(1): 172–7PubMedCrossRef
139.
Zurück zum Zitat Petitet F, Jeantaud B, Reibaud M, et al. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 1998; 63(1): PL1–6PubMedCrossRef Petitet F, Jeantaud B, Reibaud M, et al. Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of Δ9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 1998; 63(1): PL1–6PubMedCrossRef
140.
Zurück zum Zitat De Petrocellis L, Melck D, Bisogno T, et al. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999; 92(1): 377–87PubMedCrossRef De Petrocellis L, Melck D, Bisogno T, et al. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 1999; 92(1): 377–87PubMedCrossRef
141.
Zurück zum Zitat Bueb JL, Lambert DM, Tschirhart EJ. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim Biophys Acta 2001; 1538(2–3): 252–9PubMedCrossRef Bueb JL, Lambert DM, Tschirhart EJ. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim Biophys Acta 2001; 1538(2–3): 252–9PubMedCrossRef
142.
Zurück zum Zitat Hampson A. Cannabinoids as neuroprotectants against ischemia. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 101–10 Hampson A. Cannabinoids as neuroprotectants against ischemia. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 101–10
143.
Zurück zum Zitat Ralevic V, Kendall DA. Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. Eur J Pharmacol 2002; 444(3): 171–81PubMedCrossRef Ralevic V, Kendall DA. Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. Eur J Pharmacol 2002; 444(3): 171–81PubMedCrossRef
144.
Zurück zum Zitat Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 1995; 56(23–24): 2097–102PubMedCrossRef Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 1995; 56(23–24): 2097–102PubMedCrossRef
145.
Zurück zum Zitat Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2): 129–80PubMedCrossRef Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2): 129–80PubMedCrossRef
146.
Zurück zum Zitat Pertwee RG. Sites and mechanisms of action. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 73–88 Pertwee RG. Sites and mechanisms of action. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 73–88
147.
Zurück zum Zitat Schweitzer P. Cannabinoids decrease the K+ M-current in hippocampal CA1 neurons. J Neurosci 2000; 20: 51–8PubMed Schweitzer P. Cannabinoids decrease the K+ M-current in hippocampal CA1 neurons. J Neurosci 2000; 20: 51–8PubMed
148.
Zurück zum Zitat Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17: 5327–33PubMed Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 1997; 17: 5327–33PubMed
149.
Zurück zum Zitat Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54–61PubMedCrossRef Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54–61PubMedCrossRef
150.
Zurück zum Zitat Breivogel CS, Griffin G, Di Marzo V, et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60(1): 155–63PubMed Breivogel CS, Griffin G, Di Marzo V, et al. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60(1): 155–63PubMed
151.
Zurück zum Zitat Di Marzo V, Breivogel CS, Tao Q, et al. Levels, metabolism, and pharmacological activity of anandamide in CB (1) cannabinoid receptor knockout mice: evidence for non-CB (1), non-CB (2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75(6): 2434–44PubMedCrossRef Di Marzo V, Breivogel CS, Tao Q, et al. Levels, metabolism, and pharmacological activity of anandamide in CB (1) cannabinoid receptor knockout mice: evidence for non-CB (1), non-CB (2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 2000; 75(6): 2434–44PubMedCrossRef
152.
Zurück zum Zitat Pertwee RG. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci 1999; 65: 597–605PubMedCrossRef Pertwee RG. Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci 1999; 65: 597–605PubMedCrossRef
153.
Zurück zum Zitat Recht LD, Salmonsen R, Rosetti R, et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol 2001; 62(6): 755–63PubMedCrossRef Recht LD, Salmonsen R, Rosetti R, et al. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol 2001; 62(6): 755–63PubMedCrossRef
154.
Zurück zum Zitat Sanchez C, de Ceballos ML, del Pulgar TG, et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res 2001; 61(15): 5784–9PubMed Sanchez C, de Ceballos ML, del Pulgar TG, et al. Inhibition of glioma growth in vivo by selective activation of the CB2 cannabinoid receptor. Cancer Res 2001; 61(15): 5784–9PubMed
155.
Zurück zum Zitat Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298(1): 7–14PubMed Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298(1): 7–14PubMed
156.
Zurück zum Zitat Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215(1): 89–97PubMedCrossRef Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215(1): 89–97PubMedCrossRef
157.
Zurück zum Zitat De Petrocellis L, Melck D, Bisogno T, et al. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 2000; 108(1–2): 191–209PubMedCrossRef De Petrocellis L, Melck D, Bisogno T, et al. Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids 2000; 108(1–2): 191–209PubMedCrossRef
158.
Zurück zum Zitat Di Marzo V. ’Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998; 1392(2–3): 153–75PubMed Di Marzo V. ’Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1998; 1392(2–3): 153–75PubMed
159.
Zurück zum Zitat Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001; 98(16): 9371–6PubMedCrossRef Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001; 98(16): 9371–6PubMedCrossRef
160.
Zurück zum Zitat Abadji V, Lin S, Gihan T, et al. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994; 37: 1889–93PubMedCrossRef Abadji V, Lin S, Gihan T, et al. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994; 37: 1889–93PubMedCrossRef
161.
Zurück zum Zitat Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635–64PubMed Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635–64PubMed
162.
Zurück zum Zitat Walker JM, Huang SM, Strangman NM, et al. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 1999; 96(21): 12198–203PubMedCrossRef Walker JM, Huang SM, Strangman NM, et al. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 1999; 96(21): 12198–203PubMedCrossRef
163.
Zurück zum Zitat Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15(2): 300–2PubMed Baker D, Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15(2): 300–2PubMed
164.
Zurück zum Zitat Siegling A, Hofmann HA, Denzer D, et al. Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 2001; 415(1): R5–7PubMedCrossRef Siegling A, Hofmann HA, Denzer D, et al. Cannabinoid CB1 receptor upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol 2001; 415(1): R5–7PubMedCrossRef
165.
Zurück zum Zitat Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134(3): 563–70PubMedCrossRef Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001; 134(3): 563–70PubMedCrossRef
166.
Zurück zum Zitat Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410(6830): 822–5PubMedCrossRef Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410(6830): 822–5PubMedCrossRef
167.
Zurück zum Zitat Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB (1) receptors in the least shrew. Pharmacol Biochem Behav 2001; 69(1–2): 239–49PubMedCrossRef Darmani NA. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB (1) receptors in the least shrew. Pharmacol Biochem Behav 2001; 69(1–2): 239–49PubMedCrossRef
168.
Zurück zum Zitat Leweke FM, Giuffrida A, Wurster U, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10(8): 1665–9PubMedCrossRef Leweke FM, Giuffrida A, Wurster U, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999; 10(8): 1665–9PubMedCrossRef
169.
Zurück zum Zitat Beaulieu P, Bisogno T, Punwar S, et al. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 2000; 396(2–3): 85–92CrossRef Beaulieu P, Bisogno T, Punwar S, et al. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 2000; 396(2–3): 85–92CrossRef
170.
Zurück zum Zitat Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91(11): 1585–614PubMedCrossRef Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91(11): 1585–614PubMedCrossRef
171.
Zurück zum Zitat Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002 Grotenhermen F, Russo E, editors. Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002
172.
Zurück zum Zitat Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use. Canberra: Commonwealth Department of Human Services and Health, Monograph Series No. 25, 1994 Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use. Canberra: Commonwealth Department of Human Services and Health, Monograph Series No. 25, 1994
173.
Zurück zum Zitat House of Lords Select Committee on Science and Technology. Cannabis: the scientific and medical evidence. London: The Stationery Office, 1998 House of Lords Select Committee on Science and Technology. Cannabis: the scientific and medical evidence. London: The Stationery Office, 1998
174.
Zurück zum Zitat Joy JE, Watson SJ, Benson JA, editors. Marijuana and medicine: assessing the science base. Washington, DC: Institute of Medicine, National Academy Press, 1999 Joy JE, Watson SJ, Benson JA, editors. Marijuana and medicine: assessing the science base. Washington, DC: Institute of Medicine, National Academy Press, 1999
175.
Zurück zum Zitat Kalant H, Corrigal W, Hall W, et al., editors. The health effects of cannabis. Toronto (ON): Centre for Addiction and Mental Health, 1999 Kalant H, Corrigal W, Hall W, et al., editors. The health effects of cannabis. Toronto (ON): Centre for Addiction and Mental Health, 1999
176.
Zurück zum Zitat Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998; 59(2): 347–52PubMedCrossRef Sulcova E, Mechoulam R, Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998; 59(2): 347–52PubMedCrossRef
177.
Zurück zum Zitat Thompson GR, Rosenkrantz H, Schaeppi UH, et al. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol 1973; 25(3): 363–72PubMedCrossRef Thompson GR, Rosenkrantz H, Schaeppi UH, et al. Comparison of acute oral toxicity of cannabinoids in rats, dogs and monkeys. Toxicol Appl Pharmacol 1973; 25(3): 363–72PubMedCrossRef
178.
Zurück zum Zitat Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124(2–3): 200–3PubMedCrossRef Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001; 124(2–3): 200–3PubMedCrossRef
179.
Zurück zum Zitat Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103(23): 2805–9PubMedCrossRef Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation 2001; 103(23): 2805–9PubMedCrossRef
180.
181.
Zurück zum Zitat Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287(9): 1123–31PubMedCrossRef Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287(9): 1123–31PubMedCrossRef
182.
Zurück zum Zitat Lyketsos CG, Garrett E, Liang KY, et al. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 1999; 149(9): 794–800PubMedCrossRef Lyketsos CG, Garrett E, Liang KY, et al. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 1999; 149(9): 794–800PubMedCrossRef
183.
Zurück zum Zitat Pope Jr HG, Gruber AJ, Hudson JI, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58(10): 909–15PubMedCrossRef Pope Jr HG, Gruber AJ, Hudson JI, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58(10): 909–15PubMedCrossRef
184.
Zurück zum Zitat Russo E, Mathre ML, Byrne A, et al. Chronic cannabis use in the compassionate investigational new drug program: an examination of benefits and adverse effects of legal medical cannabis. J Cannabis Ther 2002; 2(1): 3–57CrossRef Russo E, Mathre ML, Byrne A, et al. Chronic cannabis use in the compassionate investigational new drug program: an examination of benefits and adverse effects of legal medical cannabis. J Cannabis Ther 2002; 2(1): 3–57CrossRef
185.
Zurück zum Zitat Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 1998; 20(3): 293–306PubMedCrossRef Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 1998; 20(3): 293–306PubMedCrossRef
186.
Zurück zum Zitat Solowij N, Grenyer BFS. Long term effects of cannabis on psyche and cognition. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 299–312 Solowij N, Grenyer BFS. Long term effects of cannabis on psyche and cognition. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 299–312
187.
Zurück zum Zitat Mattes RD, Shaw LM, Engelman K. Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults. Chem Senses 1994; 19(2): 125–40PubMedCrossRef Mattes RD, Shaw LM, Engelman K. Effects of cannabinoids (marijuana) on taste intensity and hedonic ratings and salivary flow of adults. Chem Senses 1994; 19(2): 125–40PubMedCrossRef
188.
189.
Zurück zum Zitat Lissoni P, Resentini M, Mauri R, et al. Effects of tetrahydrocannabinol on melatonin secretion in man. Horm Metab Res 1986; 18(1): 77–8PubMedCrossRef Lissoni P, Resentini M, Mauri R, et al. Effects of tetrahydrocannabinol on melatonin secretion in man. Horm Metab Res 1986; 18(1): 77–8PubMedCrossRef
190.
Zurück zum Zitat Wachtel SR, ElSohly MA, Ross SA, et al. Comparison of the subjective effects of delta (9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 2002; 161(4): 331–9PubMedCrossRef Wachtel SR, ElSohly MA, Ross SA, et al. Comparison of the subjective effects of delta (9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 2002; 161(4): 331–9PubMedCrossRef
191.
Zurück zum Zitat Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. Life Sci 1999; 65: 715–23PubMedCrossRef Hampson RE, Deadwyler SA. Cannabinoids, hippocampal function and memory. Life Sci 1999; 65: 715–23PubMedCrossRef
192.
Zurück zum Zitat Heyser CJ, Hampson RE, Deadwyler SA. Effects of delta-9-tet-rahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 1993; 264(1): 294–307PubMed Heyser CJ, Hampson RE, Deadwyler SA. Effects of delta-9-tet-rahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 1993; 264(1): 294–307PubMed
193.
Zurück zum Zitat Slikker Jr W, Paule MG, Ali SF, et al. Behavioral, neurochemical and neurohistochemical effects of chronic marijuana smoke exposure in the nonhuman primate. In: Myrphy L, Bartke A, editors. Marijuana/cannabinoids: neurobiology and neurophysiology. Boca Raton (FL): CRC Press, 1992: 219–73 Slikker Jr W, Paule MG, Ali SF, et al. Behavioral, neurochemical and neurohistochemical effects of chronic marijuana smoke exposure in the nonhuman primate. In: Myrphy L, Bartke A, editors. Marijuana/cannabinoids: neurobiology and neurophysiology. Boca Raton (FL): CRC Press, 1992: 219–73
194.
Zurück zum Zitat Kelly TH, Foltin RW, Emurian CS, et al. Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. J Anal Toxicol 1993; 17(5): 264–72PubMed Kelly TH, Foltin RW, Emurian CS, et al. Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. J Anal Toxicol 1993; 17(5): 264–72PubMed
195.
Zurück zum Zitat Perez-Reyes M. The psychologic and physiologic effects of active cannabinoids. In: Nahas G, Sutin KM, Harvey DJ, et al. Marihuana and medicine. Totowa (NJ): Humana Press, 1999: 245–52 Perez-Reyes M. The psychologic and physiologic effects of active cannabinoids. In: Nahas G, Sutin KM, Harvey DJ, et al. Marihuana and medicine. Totowa (NJ): Humana Press, 1999: 245–52
196.
Zurück zum Zitat Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65: 703–13PubMedCrossRef Sañudo-Peña MC, Tsou K, Walker JM. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 1999; 65: 703–13PubMedCrossRef
197.
Zurück zum Zitat Pertwee R. In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In: Myrphy L, Bartke A, editors. Marijuana/cannabinoids: neurobiology and neurophysiology. Boca Raton (FL): CRC Press, 1992: 165–218 Pertwee R. In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In: Myrphy L, Bartke A, editors. Marijuana/cannabinoids: neurobiology and neurophysiology. Boca Raton (FL): CRC Press, 1992: 165–218
198.
Zurück zum Zitat Domino EF. Cannabinoids and the cholinergic system. In: Nahas G, Sutin KM, Harvey DJ, et al., editors. Marihuana and medicine. Totowa (NJ): Humana Press, 1999: 223–6 Domino EF. Cannabinoids and the cholinergic system. In: Nahas G, Sutin KM, Harvey DJ, et al., editors. Marihuana and medicine. Totowa (NJ): Humana Press, 1999: 223–6
199.
Zurück zum Zitat Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995; 73(2): 907–10PubMed Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 1995; 73(2): 907–10PubMed
200.
Zurück zum Zitat Müller-Vahl KR, Kolbe H, Schneider U, et al. Movement disorders. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 205–14 Müller-Vahl KR, Kolbe H, Schneider U, et al. Movement disorders. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 205–14
201.
Zurück zum Zitat Musty RE, Consroe P. Spastic disorders. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 195–204 Musty RE, Consroe P. Spastic disorders. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 195–204
202.
Zurück zum Zitat Tashkin DP, Levisman JA, Abbasi AS, et al. Short-term effects of smoked marihuana on left ventricular function in man. Chest 1977; 72(1): 20–6PubMedCrossRef Tashkin DP, Levisman JA, Abbasi AS, et al. Short-term effects of smoked marihuana on left ventricular function in man. Chest 1977; 72(1): 20–6PubMedCrossRef
203.
Zurück zum Zitat Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 1975; 18(3): 287–97PubMed Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharmacol Ther 1975; 18(3): 287–97PubMed
204.
Zurück zum Zitat Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L., on human and rabbit platelet aggregation. J Pharm Pharmacol 1989; 41(10): 705–9PubMedCrossRef Formukong EA, Evans AT, Evans FJ. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L., on human and rabbit platelet aggregation. J Pharm Pharmacol 1989; 41(10): 705–9PubMedCrossRef
205.
Zurück zum Zitat O’Leary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002; 26(6): 802–16PubMedCrossRef O’Leary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 2002; 26(6): 802–16PubMedCrossRef
206.
Zurück zum Zitat Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 1998; 76(12): 824–36PubMedCrossRef Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 1998; 76(12): 824–36PubMedCrossRef
207.
Zurück zum Zitat Wagner JA, Jarai Z, Batkai S, et al. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol 2001; 423(2–3): 203–10PubMedCrossRef Wagner JA, Jarai Z, Batkai S, et al. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur J Pharmacol 2001; 423(2–3): 203–10PubMedCrossRef
208.
Zurück zum Zitat Van Klingeren B, Ten Ham M. Antibacterial activity of Δ9-tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek 1976; 42(1–2): 9–12PubMedCrossRef Van Klingeren B, Ten Ham M. Antibacterial activity of Δ9-tetrahydrocannabinol and cannabidiol. Antonie Van Leeuwenhoek 1976; 42(1–2): 9–12PubMedCrossRef
209.
Zurück zum Zitat Lancz G, Specter S, Brown HK. Suppressive effect of delta-9-tetrahydrocannabinol on herpes simplex virus infectivity in vitro. Proc Soc Exp Biol Med 1991; 196(4): 401–4PubMed Lancz G, Specter S, Brown HK. Suppressive effect of delta-9-tetrahydrocannabinol on herpes simplex virus infectivity in vitro. Proc Soc Exp Biol Med 1991; 196(4): 401–4PubMed
210.
Zurück zum Zitat Pate D. Glaucoma and cannabinoids. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 215–24 Pate D. Glaucoma and cannabinoids. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 215–24
211.
Zurück zum Zitat Colasanti BK. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul Pharmacol 1990; 6(4): 259–69PubMedCrossRef Colasanti BK. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul Pharmacol 1990; 6(4): 259–69PubMedCrossRef
212.
Zurück zum Zitat Murphy L. Hormonal system and reproduction. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 289–98 Murphy L. Hormonal system and reproduction. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 289–98
213.
Zurück zum Zitat Tahir SK, Trogadis JE, Stevens JK, et al. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem Cell Biol 1992; 70(10–11): 1159–73PubMedCrossRef Tahir SK, Trogadis JE, Stevens JK, et al. Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells. Biochem Cell Biol 1992; 70(10–11): 1159–73PubMedCrossRef
214.
Zurück zum Zitat De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 1998; 95(14): 8375–80PubMedCrossRef De Petrocellis L, Melck D, Palmisano A, et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 1998; 95(14): 8375–80PubMedCrossRef
215.
Zurück zum Zitat Melck D, De Petrocellis L, Orlando P, et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000; 141(1): 118–26PubMedCrossRef Melck D, De Petrocellis L, Orlando P, et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000; 141(1): 118–26PubMedCrossRef
216.
Zurück zum Zitat Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6(3): 313–9PubMedCrossRef Galve-Roperh I, Sanchez C, Cortes ML, et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6(3): 313–9PubMedCrossRef
217.
Zurück zum Zitat Cabral G. Immune system. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 279–88 Cabral G. Immune system. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 279–88
218.
Zurück zum Zitat Melamede R. Possible mechanisms in autoimmune diseases. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 111–22 Melamede R. Possible mechanisms in autoimmune diseases. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 111–22
219.
Zurück zum Zitat Evans AT, Formukong EA, Evans FJ. Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential. Biochem Pharmacol 1987; 36(12): 2035–7PubMedCrossRef Evans AT, Formukong EA, Evans FJ. Actions of cannabis constituents on enzymes of arachidonate metabolism: anti-inflammatory potential. Biochem Pharmacol 1987; 36(12): 2035–7PubMedCrossRef
220.
Zurück zum Zitat Sofia RD, Nalepa SD, Harakal JJ, et al. Anti-edema and analgesic properties of Δ9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther 1973; 186(3): 646–55PubMed Sofia RD, Nalepa SD, Harakal JJ, et al. Anti-edema and analgesic properties of Δ9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther 1973; 186(3): 646–55PubMed
221.
Zurück zum Zitat Hembree III WC, Nahas GG, Zeidenberg P, et al. Changes in human spermatozoa associated with high dose marihuana smoking. Adv Biosci 1978; 22–23: 429–39PubMed Hembree III WC, Nahas GG, Zeidenberg P, et al. Changes in human spermatozoa associated with high dose marihuana smoking. Adv Biosci 1978; 22–23: 429–39PubMed
222.
Zurück zum Zitat Chang MC, Berkery D, Schuel R, et al. Evidence for a can nabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Reprod Dev 1993; 36(4): 507–16PubMedCrossRef Chang MC, Berkery D, Schuel R, et al. Evidence for a can nabinoid receptor in sea urchin sperm and its role in blockade of the acrosome reaction. Mol Reprod Dev 1993; 36(4): 507–16PubMedCrossRef
223.
Zurück zum Zitat Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999; 143(3): 315–7PubMedCrossRef Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology 1999; 143(3): 315–7PubMedCrossRef
224.
Zurück zum Zitat Williams CM, Kirkham TC. Observational analysis of feeding induced by delta (9)-THC and anandamide. Physiol Behav 2002; 76(2): 241–50PubMedCrossRef Williams CM, Kirkham TC. Observational analysis of feeding induced by delta (9)-THC and anandamide. Physiol Behav 2002; 76(2): 241–50PubMedCrossRef
225.
Zurück zum Zitat Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989; 249(2): 444–9PubMed Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989; 249(2): 444–9PubMed
226.
Zurück zum Zitat McCallum RW, Soykan I, Sridhar KR, et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13(1): 77–80PubMedCrossRef McCallum RW, Soykan I, Sridhar KR, et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13(1): 77–80PubMedCrossRef
227.
Zurück zum Zitat Coruzzi G, Adami M, Coppelli G, et al. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 1999; 360(6): 715–8PubMedCrossRef Coruzzi G, Adami M, Coppelli G, et al. Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. Naunyn Schmiedebergs Arch Pharmacol 1999; 360(6): 715–8PubMedCrossRef
228.
Zurück zum Zitat Adami M, Frati P, Bertini S, et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 2002; 135(7): 1598–606PubMedCrossRef Adami M, Frati P, Bertini S, et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 2002; 135(7): 1598–606PubMedCrossRef
229.
Zurück zum Zitat Lemberger L, Crabtree RE, Rowe HM. 11-Hydroxy-Δ9-tetra-hydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science 1972; 177(43): 62–4PubMedCrossRef Lemberger L, Crabtree RE, Rowe HM. 11-Hydroxy-Δ9-tetra-hydrocannabinol: pharmacology, disposition, and metabolism of a major metabolite of marihuana in man. Science 1972; 177(43): 62–4PubMedCrossRef
230.
Zurück zum Zitat Perez-Reyes M, Timmons M, Lipton M, et al. Intravenous injection in man of delta-9- tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol. Science 1972; 177(49): 633–5PubMedCrossRef Perez-Reyes M, Timmons M, Lipton M, et al. Intravenous injection in man of delta-9- tetrahydrocannabinol and 11-OH-delta-9-tetrahydrocannabinol. Science 1972; 177(49): 633–5PubMedCrossRef
231.
Zurück zum Zitat Karler R, Turkanis SA. Different cannabinoids exhibit different pharmacological and toxicological properties. NIDA Res Monogr 1987; 79: 96–107PubMed Karler R, Turkanis SA. Different cannabinoids exhibit different pharmacological and toxicological properties. NIDA Res Monogr 1987; 79: 96–107PubMed
232.
Zurück zum Zitat Burstein SH, Audette CA, Doyle SA, et al. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid. J Pharmacol Exp Ther 1989; 251(2): 531–5PubMed Burstein SH, Audette CA, Doyle SA, et al. Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid. J Pharmacol Exp Ther 1989; 251(2): 531–5PubMed
233.
Zurück zum Zitat Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 1999; 82(1): 87–96PubMedCrossRef Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 1999; 82(1): 87–96PubMedCrossRef
234.
Zurück zum Zitat Doyle SA, Burstein SH, Dewey WL, et al. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. Agents Actions 1990; 31(1–2): 157–63PubMedCrossRef Doyle SA, Burstein SH, Dewey WL, et al. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. Agents Actions 1990; 31(1–2): 157–63PubMedCrossRef
235.
Zurück zum Zitat Burstein S, Hunter SA, Latham V, et al. A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice. Experientia 1987; 43(4): 402–3PubMedCrossRef Burstein S, Hunter SA, Latham V, et al. A major metabolite of delta 1-tetrahydrocannabinol reduces its cataleptic effect in mice. Experientia 1987; 43(4): 402–3PubMedCrossRef
236.
Zurück zum Zitat Zuardi AW, Guimarães FS, Guimarães VMC, et al. Cannabidiol: possible therapeutic application. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 359–70 Zuardi AW, Guimarães FS, Guimarães VMC, et al. Cannabidiol: possible therapeutic application. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 359–70
237.
Zurück zum Zitat Karler R, Turkanis SA. The cannabinoids as potential antiepileptics. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 437S–48SPubMed Karler R, Turkanis SA. The cannabinoids as potential antiepileptics. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 437S–48SPubMed
238.
Zurück zum Zitat Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986; 30(4): 277–82PubMedCrossRef Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986; 30(4): 277–82PubMedCrossRef
239.
Zurück zum Zitat Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a nonpsychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002; 13(5): 567–70PubMedCrossRef Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a nonpsychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002; 13(5): 567–70PubMedCrossRef
240.
Zurück zum Zitat Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral antiarthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000; 97(17): 9561–6PubMedCrossRef Malfait AM, Gallily R, Sumariwalla PF, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral antiarthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 2000; 97(17): 9561–6PubMedCrossRef
241.
Zurück zum Zitat Colasanti BK, Brown RE, Craig CR. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol 1984; 15(6): 479–84PubMedCrossRef Colasanti BK, Brown RE, Craig CR. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Gen Pharmacol 1984; 15(6): 479–84PubMedCrossRef
242.
Zurück zum Zitat Baek SH, Kim YO, Kwag JS, et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII): antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 1998; 21(3): 353–6PubMedCrossRef Baek SH, Kim YO, Kwag JS, et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent (VII): antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 1998; 21(3): 353–6PubMedCrossRef
243.
Zurück zum Zitat Fride E, Barg J, Levy R, et al. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1995; 272(2): 699–707PubMed Fride E, Barg J, Levy R, et al. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1995; 272(2): 699–707PubMed
244.
Zurück zum Zitat Archer RA, Stark P, Lemberger L. Nabilone. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press, 1986: 85–103 Archer RA, Stark P, Lemberger L. Nabilone. In: Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press, 1986: 85–103
245.
Zurück zum Zitat Little PJ, Compton DR, Mechoulam R, et al. Stereochemical effects of 11-OH-Δ8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 1989; 32: 661–6PubMedCrossRef Little PJ, Compton DR, Mechoulam R, et al. Stereochemical effects of 11-OH-Δ8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 1989; 32: 661–6PubMedCrossRef
246.
Zurück zum Zitat Ottani A, Giuliani D. Hu 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 2001; 7(2): 131–45PubMedCrossRef Ottani A, Giuliani D. Hu 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 2001; 7(2): 131–45PubMedCrossRef
247.
Zurück zum Zitat Titishov N, Mechoulam R, Zimmerman AM. Stereospecific effects of (−)- and (+)-7-hydroxy-delta-6-tetrahydrocannabinol-dimethylheptyl on the immune system of mice. Pharmacology 1989; 39(6): 337–49PubMedCrossRef Titishov N, Mechoulam R, Zimmerman AM. Stereospecific effects of (−)- and (+)-7-hydroxy-delta-6-tetrahydrocannabinol-dimethylheptyl on the immune system of mice. Pharmacology 1989; 39(6): 337–49PubMedCrossRef
248.
Zurück zum Zitat Mechoulam R, Shohami E. HU-211: cannabinoid neuroprotective agent. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 389–400 Mechoulam R, Shohami E. HU-211: cannabinoid neuroprotective agent. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 389–400
249.
Zurück zum Zitat Burstein S. Therapeutic potential of ajulemic acid (CT3). In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 381–8 Burstein S. Therapeutic potential of ajulemic acid (CT3). In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 381–8
250.
Zurück zum Zitat Jain AK, Ryan JR, McMahon FG, et al. Evaluation of intramuscular levonantrodol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 320S–6SPubMed Jain AK, Ryan JR, McMahon FG, et al. Evaluation of intramuscular levonantrodol and placebo in acute postoperative pain. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 320S–6SPubMed
251.
Zurück zum Zitat Citron ML, Herman TS, Vreeland F, et al. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1985; 69: 109–12PubMed Citron ML, Herman TS, Vreeland F, et al. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep 1985; 69: 109–12PubMed
252.
Zurück zum Zitat Lucraft HH, Palmer MK. Randomized clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 1982; 33(6): 621–2PubMedCrossRef Lucraft HH, Palmer MK. Randomized clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Clin Radiol 1982; 33(6): 621–2PubMedCrossRef
253.
Zurück zum Zitat Showalter VM, Compton DR, Martin BR, et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996; 278(3): 989–99PubMed Showalter VM, Compton DR, Martin BR, et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996; 278(3): 989–99PubMed
254.
Zurück zum Zitat Melvin LS, Milne GM, Johnson MR, et al. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993; 44(5): 1008–15PubMed Melvin LS, Milne GM, Johnson MR, et al. Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 1993; 44(5): 1008–15PubMed
255.
Zurück zum Zitat Beltramo M, Stella N, Calignano A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277(5329): 1094–7PubMedCrossRef Beltramo M, Stella N, Calignano A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997; 277(5329): 1094–7PubMedCrossRef
256.
Zurück zum Zitat Jaggar SI, Hasnie FS, Sellaturay S, et al. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76(1–2): 189–99PubMedCrossRef Jaggar SI, Hasnie FS, Sellaturay S, et al. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76(1–2): 189–99PubMedCrossRef
257.
Zurück zum Zitat Terranova J-P, Storme J-J, Lafon N, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 1996; 126: 165–72PubMedCrossRef Terranova J-P, Storme J-J, Lafon N, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 1996; 126: 165–72PubMedCrossRef
258.
Zurück zum Zitat Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58(4): 322–8PubMedCrossRef Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry 2001; 58(4): 322–8PubMedCrossRef
259.
Zurück zum Zitat Di Marzo V, Hill MP, Bisogno T, et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J 2000; 14(10): 1432–8PubMedCrossRef Di Marzo V, Hill MP, Bisogno T, et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB J 2000; 14(10): 1432–8PubMedCrossRef
260.
Zurück zum Zitat Müller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington’s disease. Mov Disord 1999; 14(6): 1038–40PubMedCrossRef Müller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington’s disease. Mov Disord 1999; 14(6): 1038–40PubMedCrossRef
261.
Zurück zum Zitat Romero J, Garcia-Palomero E, Castro JG, et al. Effects of chronic exposure to Δ9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 1997; 46(1–2): 100–8PubMedCrossRef Romero J, Garcia-Palomero E, Castro JG, et al. Effects of chronic exposure to Δ9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Brain Res Mol Brain Res 1997; 46(1–2): 100–8PubMedCrossRef
262.
Zurück zum Zitat Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976; 282: 221–39PubMedCrossRef Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci 1976; 282: 221–39PubMedCrossRef
263.
Zurück zum Zitat Stefanis C. Biological aspects of cannabis use. NIDA Res Monogr 1978; 19: 149–78PubMed Stefanis C. Biological aspects of cannabis use. NIDA Res Monogr 1978; 19: 149–78PubMed
264.
Zurück zum Zitat Bass CE, Martin BR. Time course for the induction and maintenance of tolerance to Delta (9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 2000; 60(2): 113–9PubMedCrossRef Bass CE, Martin BR. Time course for the induction and maintenance of tolerance to Delta (9)-tetrahydrocannabinol in mice. Drug Alcohol Depend 2000; 60(2): 113–9PubMedCrossRef
265.
Zurück zum Zitat Luthra YK, Esber HJ, Lariviere DM, et al. Assessment of tolerance to immunosuppressive activity of delta 9-tetrahydrocannabinol in rats. J Immunopharmacol 1980; 2(2): 245–56PubMedCrossRef Luthra YK, Esber HJ, Lariviere DM, et al. Assessment of tolerance to immunosuppressive activity of delta 9-tetrahydrocannabinol in rats. J Immunopharmacol 1980; 2(2): 245–56PubMedCrossRef
266.
Zurück zum Zitat Miczek KA, Dixit BN. Behavioral and biochemical effects of chronic delta 9-tetrahydrocannabinol in rats. Psychopharmacology (Berl) 1980; 67(2): 195–202CrossRef Miczek KA, Dixit BN. Behavioral and biochemical effects of chronic delta 9-tetrahydrocannabinol in rats. Psychopharmacology (Berl) 1980; 67(2): 195–202CrossRef
267.
Zurück zum Zitat Smith CG, Almirez RG, Berenberg J, et al. Tolerance develops to the disruptive effects of delta 9-tetrahydrocannabinol on primate menstrual cycle. Science 1983; 219(4591): 1453–5PubMedCrossRef Smith CG, Almirez RG, Berenberg J, et al. Tolerance develops to the disruptive effects of delta 9-tetrahydrocannabinol on primate menstrual cycle. Science 1983; 219(4591): 1453–5PubMedCrossRef
268.
Zurück zum Zitat Di Marzo V, Berrendero F, Bisogno T, et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9-tetrahydrocannabinol-tolerant rats. J Neurochem 2000; 74(4): 1627–35PubMedCrossRef Di Marzo V, Berrendero F, Bisogno T, et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9-tetrahydrocannabinol-tolerant rats. J Neurochem 2000; 74(4): 1627–35PubMedCrossRef
269.
Zurück zum Zitat Rubino T, Vigano D, Massi P, et al. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 2000; 75(5): 2080–6PubMedCrossRef Rubino T, Vigano D, Massi P, et al. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940. J Neurochem 2000; 75(5): 2080–6PubMedCrossRef
270.
Zurück zum Zitat Abood ME, Sauss C, Fan F, et al. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 1993; 46(3): 575–9PubMedCrossRef Abood ME, Sauss C, Fan F, et al. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav 1993; 46(3): 575–9PubMedCrossRef
271.
Zurück zum Zitat Rubino T, Vigano D, Costa B, et al. Loss of cannabinoid-stimulated guanosine 5′-O- (3-[35S]thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. J Neurochem 2000; 75(6): 2478–84PubMedCrossRef Rubino T, Vigano D, Costa B, et al. Loss of cannabinoid-stimulated guanosine 5′-O- (3-[35S]thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. J Neurochem 2000; 75(6): 2478–84PubMedCrossRef
272.
Zurück zum Zitat Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior. Compr Psychiatry 1979; 20(5): 427–32PubMedCrossRef Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior. Compr Psychiatry 1979; 20(5): 427–32PubMedCrossRef
273.
Zurück zum Zitat Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2: 244–68CrossRef Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2: 244–68CrossRef
274.
Zurück zum Zitat Kleiber D, Soellner R, Tossmann P. Cannabiskonsum in der Bundesrepublik Deutschland: Entwicklungstendenzen, Konsummuster und Einflußfaktoren. Bonn: Federal Ministry of Health, 1997 Kleiber D, Soellner R, Tossmann P. Cannabiskonsum in der Bundesrepublik Deutschland: Entwicklungstendenzen, Konsummuster und Einflußfaktoren. Bonn: Federal Ministry of Health, 1997
275.
Zurück zum Zitat Roques B. Problemes posées par la dangerosité des drogues. Rapport du professeur Bernhard Roques au Secrétaire d’Etat à la Santé. Paris, 1998 Roques B. Problemes posées par la dangerosité des drogues. Rapport du professeur Bernhard Roques au Secrétaire d’Etat à la Santé. Paris, 1998
276.
Zurück zum Zitat Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol®). J Psychoactive Drugs 1998; 30(2): 187–96PubMedCrossRef Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol®). J Psychoactive Drugs 1998; 30(2): 187–96PubMedCrossRef
277.
Zurück zum Zitat British Medical Association. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers, 1997 British Medical Association. Therapeutic uses of cannabis. Amsterdam: Harwood Academic Publishers, 1997
278.
Zurück zum Zitat Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. New Haven (CT): Yale University Press, 1993 Grinspoon L, Bakalar JB. Marihuana, the forbidden medicine. New Haven (CT): Yale University Press, 1993
279.
Zurück zum Zitat Grotenhermen F. Review of therapeutic effects. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 123–42 Grotenhermen F. Review of therapeutic effects. In: Grotenhermen F, Russo E, editors. Cannabis and cannabinoids: pharmacology, toxicology, and therapeutic potential. Binghamton (NY): Haworth Press, 2002: 123–42
280.
Zurück zum Zitat Mathre ML, editor. Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. Jefferson (NC): McFarland & Co, 1997 Mathre ML, editor. Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. Jefferson (NC): McFarland & Co, 1997
281.
Zurück zum Zitat Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press, 1986 Mechoulam R, editor. Cannabinoids as therapeutic agents. Boca Raton: CRC Press, 1986
282.
Zurück zum Zitat Dansak DA. As an antiemetic and appetite stimulant in cancer patients. In: Mathre ML, editor. Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. Jefferson (NC): McFarland & Co, 1997: 69–83 Dansak DA. As an antiemetic and appetite stimulant in cancer patients. In: Mathre ML, editor. Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana. Jefferson (NC): McFarland & Co, 1997: 69–83
283.
Zurück zum Zitat Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 1991; 6(6): 352–9PubMedCrossRef Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. J Pain Symptom Manage 1991; 6(6): 352–9PubMedCrossRef
284.
Zurück zum Zitat Sallan SE, Cronin C, Zelen M, et al. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302(3): 135–8PubMedCrossRef Sallan SE, Cronin C, Zelen M, et al. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302(3): 135–8PubMedCrossRef
285.
Zurück zum Zitat Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14(1): 7–14PubMedCrossRef Beal JE, Olson R, Lefkowitz L, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 1997; 14(1): 7–14PubMedCrossRef
286.
Zurück zum Zitat Plasse TF, Gorter RW, Krasnow SH, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40(3): 695–700PubMedCrossRef Plasse TF, Gorter RW, Krasnow SH, et al. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991; 40(3): 695–700PubMedCrossRef
287.
Zurück zum Zitat Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10(2): 89–97PubMedCrossRef Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995; 10(2): 89–97PubMedCrossRef
288.
Zurück zum Zitat Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancerassociated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20(2): 567–73PubMedCrossRef Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancerassociated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20(2): 567–73PubMedCrossRef
289.
Zurück zum Zitat Soderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav 2001; 69(3–4): 343–50PubMedCrossRef Soderpalm AH, Schuster A, de Wit H. Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav 2001; 69(3–4): 343–50PubMedCrossRef
290.
Zurück zum Zitat Maurer M, Henn V, Dittrich A, et al. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Neurol Sci 1990; 240(1): 1–4CrossRef Maurer M, Henn V, Dittrich A, et al. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Neurol Sci 1990; 240(1): 1–4CrossRef
291.
Zurück zum Zitat Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980; 21(1): 81–5PubMed Petro DJ. Marihuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 1980; 21(1): 81–5PubMed
292.
Zurück zum Zitat Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58(9): 1404–7PubMedCrossRef Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 2002; 58(9): 1404–7PubMedCrossRef
293.
Zurück zum Zitat Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis [letter]. Lancet 1995; 345(8949): 579PubMedCrossRef Martyn CN, Illis LS, Thom J. Nabilone in the treatment of multiple sclerosis [letter]. Lancet 1995; 345(8949): 579PubMedCrossRef
294.
Zurück zum Zitat Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236(2): 120–2PubMedCrossRef Meinck HM, Schonle PW, Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236(2): 120–2PubMedCrossRef
295.
Zurück zum Zitat Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 413S–6SPubMed Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21 (8–9 Suppl.): 413S–6SPubMed
296.
Zurück zum Zitat Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7(1): 39–50PubMedCrossRef Ungerleider JT, Andyrsiak T, Fairbanks L, et al. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7(1): 39–50PubMedCrossRef
297.
Zurück zum Zitat Elsner F, Radbruch L, Sabatowski R. Tetrahydrocannabinol zur Therapie chronischer Schmerzen [Tetrahydrocannabinol for treatment of chronic pain]. Schmerz 2001; 15(3): 200–4PubMedCrossRef Elsner F, Radbruch L, Sabatowski R. Tetrahydrocannabinol zur Therapie chronischer Schmerzen [Tetrahydrocannabinol for treatment of chronic pain]. Schmerz 2001; 15(3): 200–4PubMedCrossRef
298.
Zurück zum Zitat Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts in chronic pain: (2) comparison of two patients with back pain and sciatica. Congress on Cannabis and the Cannabinoids. Cologne: International Association for Cannabis as Medicine, 2001 Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts in chronic pain: (2) comparison of two patients with back pain and sciatica. Congress on Cannabis and the Cannabinoids. Cologne: International Association for Cannabis as Medicine, 2001
299.
Zurück zum Zitat Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts in chronic pain: (3) comparison of two patients with multiple sclerosis. Congress on Cannabis and the Cannabinoids. Cologne: International Association for Cannabis as Medicine, 2001 Notcutt W, Price M, Miller R, et al. Medicinal cannabis extracts in chronic pain: (3) comparison of two patients with multiple sclerosis. Congress on Cannabis and the Cannabinoids. Cologne: International Association for Cannabis as Medicine, 2001
300.
Zurück zum Zitat Noyes Jr R, Brunk SF, Avery DAH, et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18(1): 84–9PubMed Noyes Jr R, Brunk SF, Avery DAH, et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18(1): 84–9PubMed
301.
Zurück zum Zitat Noyes Jr R, Brunk SF, Baram DA, et al. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15(2–3): 139–43PubMed Noyes Jr R, Brunk SF, Baram DA, et al. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1975; 15(2–3): 139–43PubMed
302.
Zurück zum Zitat Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13(6): 669–71PubMedCrossRef Clifford DB. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 1983; 13(6): 669–71PubMedCrossRef
303.
Zurück zum Zitat Fox SH, Kellett M, Moore AP, et al. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002; 17(1): 145–9PubMedCrossRef Fox SH, Kellett M, Moore AP, et al. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 2002; 17(1): 145–9PubMedCrossRef
304.
Zurück zum Zitat Hemming M, Yellowlees PM. Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol 1993; 7: 389–91PubMedCrossRef Hemming M, Yellowlees PM. Effective treatment of Tourette’s syndrome with marijuana. J Psychopharmacol 1993; 7: 389–91PubMedCrossRef
305.
Zurück zum Zitat Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol [letter]. Am J Psychiatry 1999; 156(3): 495PubMed Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette’s syndrome with delta-9-tetrahydrocannabinol [letter]. Am J Psychiatry 1999; 156(3): 495PubMed
306.
Zurück zum Zitat Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35(2): 57–61PubMedCrossRef Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Δ9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35(2): 57–61PubMedCrossRef
307.
Zurück zum Zitat Sandyk R, Awerbuch G. Marijuana and Tourette’s syndrome [letter]. J Clin Psychopharmacol 1998; 8: 844 Sandyk R, Awerbuch G. Marijuana and Tourette’s syndrome [letter]. J Clin Psychopharmacol 1998; 8: 844
308.
Zurück zum Zitat Sieradzan KA, Fox SH, Hill M, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 2001; 57(11): 2108–11PubMedCrossRef Sieradzan KA, Fox SH, Hill M, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study. Neurology 2001; 57(11): 2108–11PubMedCrossRef
309.
Zurück zum Zitat Hartley JP, Nogrady SG, Seaton A. Bronchodilator effect of delta1-tetrahydrocannabinol. Br J Clin Pharmacol 1978; 5(6): 523–5PubMedCrossRef Hartley JP, Nogrady SG, Seaton A. Bronchodilator effect of delta1-tetrahydrocannabinol. Br J Clin Pharmacol 1978; 5(6): 523–5PubMedCrossRef
310.
Zurück zum Zitat Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral Δ9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis 1974; 109(4): 420–8PubMed Tashkin DP, Shapiro BJ, Frank IM. Acute effects of smoked marijuana and oral Δ9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis 1974; 109(4): 420–8PubMed
311.
Zurück zum Zitat Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 1979; 17(5): 191–6PubMed Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 1979; 17(5): 191–6PubMed
312.
Zurück zum Zitat Hepler RS, Frank IR. Marihuana smoking and intraocular pressure [letter]. JAMA 1971; 217(10): 1392PubMedCrossRef Hepler RS, Frank IR. Marihuana smoking and intraocular pressure [letter]. JAMA 1971; 217(10): 1392PubMedCrossRef
313.
Zurück zum Zitat Hepler RS, Petrus RJ. Experiences with administration of marihuana to glaucoma patients. In: Cohen S, Stillman RC, editors. The therapeutic potential of marihuana. New York: Plenum Medical Book, 1976: 63–75CrossRef Hepler RS, Petrus RJ. Experiences with administration of marihuana to glaucoma patients. In: Cohen S, Stillman RC, editors. The therapeutic potential of marihuana. New York: Plenum Medical Book, 1976: 63–75CrossRef
314.
Zurück zum Zitat Merritt JC, Crawford WJ, Alexander PC, et al. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980; 87(3): 222–8PubMed Merritt JC, Crawford WJ, Alexander PC, et al. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology 1980; 87(3): 222–8PubMed
315.
Zurück zum Zitat Schnelle M, Grotenhermen F, Reif M, et al. Ergebnisse einer standardisierten Umfrage zur medizinischen Verwendung von Cannabisprodukten im deutschen Sprachraum, [Results of a standardized survey on the medical use of cannabis products in the German-speaking area]. Forsch Komplementarmed [Res Complementary Med] 1999: 36 Schnelle M, Grotenhermen F, Reif M, et al. Ergebnisse einer standardisierten Umfrage zur medizinischen Verwendung von Cannabisprodukten im deutschen Sprachraum, [Results of a standardized survey on the medical use of cannabis products in the German-speaking area]. Forsch Komplementarmed [Res Complementary Med] 1999: 36
316.
Zurück zum Zitat Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42(10): 1266–72PubMedCrossRef Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42(10): 1266–72PubMedCrossRef
317.
Zurück zum Zitat Gilson I, Busalacchi M. Marijuana for intractable hiccups [letter]. Lancet 1998; 351(9098): 267PubMedCrossRef Gilson I, Busalacchi M. Marijuana for intractable hiccups [letter]. Lancet 1998; 351(9098): 267PubMedCrossRef
318.
Zurück zum Zitat Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 1998; 30(2): 171–7PubMedCrossRef Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. J Psychoactive Drugs 1998; 30(2): 171–7PubMedCrossRef
319.
Zurück zum Zitat Mikuriya TH. Cannabis substitution: an adjunctive therapeutic tool in the treatment of alcoholism. Med Times 1970; 98(4): 187–91PubMed Mikuriya TH. Cannabis substitution: an adjunctive therapeutic tool in the treatment of alcoholism. Med Times 1970; 98(4): 187–91PubMed
320.
Zurück zum Zitat Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12(9): 913–9PubMedCrossRef Volicer L, Stelly M, Morris J, et al. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997; 12(9): 913–9PubMedCrossRef
321.
Zurück zum Zitat Ralevic V, Kendall DA. Cannabinoid inhibition of capsaicinsensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 2001; 418(1–2): 117–25PubMedCrossRef Ralevic V, Kendall DA. Cannabinoid inhibition of capsaicinsensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 2001; 418(1–2): 117–25PubMedCrossRef
322.
Zurück zum Zitat Jacobsson SO, Wallin T, Fowler CJ. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids: relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 2001; 299(3): 951–9PubMed Jacobsson SO, Wallin T, Fowler CJ. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids: relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 2001; 299(3): 951–9PubMed
323.
Zurück zum Zitat Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001; 78(11): 613–25PubMedCrossRef Guzman M, Sanchez C, Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med 2001; 78(11): 613–25PubMedCrossRef
324.
Zurück zum Zitat Izzo AA, Pinto L, Borrelli F, et al. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000; 129(8): 1627–32PubMedCrossRef Izzo AA, Pinto L, Borrelli F, et al. Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. Br J Pharmacol 2000; 129(8): 1627–32PubMedCrossRef
325.
Zurück zum Zitat Calignano A, Katona I, Desarnaud F, et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000; 408(6808): 96–101PubMedCrossRef Calignano A, Katona I, Desarnaud F, et al. Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature 2000; 408(6808): 96–101PubMedCrossRef
326.
Zurück zum Zitat Carley DW, Paviovic S, Janelidze M, et al. Functional role for cannabinoids in respiratory stability during sleep. Sleep 2002; 25(4): 391–8PubMed Carley DW, Paviovic S, Janelidze M, et al. Functional role for cannabinoids in respiratory stability during sleep. Sleep 2002; 25(4): 391–8PubMed
327.
Zurück zum Zitat Pryor GT, Husain S, Mitoma C. Acute and subacute interactions between delta-9-tetrahydrocannabinol and other drugs in the rat. Ann N Y Acad Sci 1976; 281: 171–89PubMedCrossRef Pryor GT, Husain S, Mitoma C. Acute and subacute interactions between delta-9-tetrahydrocannabinol and other drugs in the rat. Ann N Y Acad Sci 1976; 281: 171–89PubMedCrossRef
328.
Zurück zum Zitat Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16(4): 543–50PubMedCrossRef Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002; 16(4): 543–50PubMedCrossRef
329.
Zurück zum Zitat Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17(3): 141–3PubMedCrossRef Zullino DF, Delessert D, Eap CB, et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17(3): 141–3PubMedCrossRef
330.
Zurück zum Zitat Hollister LE. Interactions of marihuana and Δ9-THC with other drugs. In: Nahas G, Sutin KM, Harvey DJ, et al., editors. Marihuana and medicine. Totowa (NJ): Humana Press, 1999: 273–7 Hollister LE. Interactions of marihuana and Δ9-THC with other drugs. In: Nahas G, Sutin KM, Harvey DJ, et al., editors. Marihuana and medicine. Totowa (NJ): Humana Press, 1999: 273–7
331.
Zurück zum Zitat Sutin KM, Nahas GG. Physiological and pharmacological interactions of marihuana (Δ9-THC) with drugs and anesthetics. In: Nahas G, Sutin KM, Harvey DJ, et al., editors. Marihuana and medicine. Totowa (NJ): Humana Press, 1999: 253–71 Sutin KM, Nahas GG. Physiological and pharmacological interactions of marihuana (Δ9-THC) with drugs and anesthetics. In: Nahas G, Sutin KM, Harvey DJ, et al., editors. Marihuana and medicine. Totowa (NJ): Humana Press, 1999: 253–71
332.
Zurück zum Zitat Brody S, Preut R. Cannabis, tobacco, and caffeine use modify the blood pressure reactivity protection of ascorbic acid. Pharmacol Biochem Behav 2002; 72(4): 811–6PubMedCrossRef Brody S, Preut R. Cannabis, tobacco, and caffeine use modify the blood pressure reactivity protection of ascorbic acid. Pharmacol Biochem Behav 2002; 72(4): 811–6PubMedCrossRef
333.
Zurück zum Zitat Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 848(1–2): 183–90PubMedCrossRef Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 848(1–2): 183–90PubMedCrossRef
334.
Zurück zum Zitat Koe BK, Milne GM, Weissman A, et al. Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Pharmacol 1985; 109(2): 201–12PubMedCrossRef Koe BK, Milne GM, Weissman A, et al. Enhancement of brain [3H]flunitrazepam binding and analgesic activity of synthetic cannabimimetics. Eur J Pharmacol 1985; 109(2): 201–12PubMedCrossRef
335.
Zurück zum Zitat Moss DE, Manderscheid PZ, Montgomery SP, et al. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 1989; 44(21): 1521–5PubMedCrossRef Moss DE, Manderscheid PZ, Montgomery SP, et al. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 1989; 44(21): 1521–5PubMedCrossRef
336.
Zurück zum Zitat Perez-Reyes M, Burstein SH, White WR, et al. Antagonism of marihuana effects by indomethacin in humans. Life Sci 1991; 48(6): 507–15PubMedCrossRef Perez-Reyes M, Burstein SH, White WR, et al. Antagonism of marihuana effects by indomethacin in humans. Life Sci 1991; 48(6): 507–15PubMedCrossRef
337.
Zurück zum Zitat Green K, Kearse EC, McIntyre OL. Interaction between delta-9-tetrahydrocannabinol and indomethacin. Ophthalmic Res 2001; 33(4): 217–20PubMedCrossRef Green K, Kearse EC, McIntyre OL. Interaction between delta-9-tetrahydrocannabinol and indomethacin. Ophthalmic Res 2001; 33(4): 217–20PubMedCrossRef
338.
Zurück zum Zitat Mechoulam R, Hanus L, Fride E. Towards cannabinoid drugs: revisited. Prog Med Chem 1998; 35: 199–243PubMedCrossRef Mechoulam R, Hanus L, Fride E. Towards cannabinoid drugs: revisited. Prog Med Chem 1998; 35: 199–243PubMedCrossRef
339.
Zurück zum Zitat Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134(4): 845–52PubMedCrossRef Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001; 134(4): 845–52PubMedCrossRef
Metadaten
Titel
Pharmacokinetics and Pharmacodynamics of Cannabinoids
verfasst von
Dr Franjo Grotenhermen
Publikationsdatum
01.04.2003
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 4/2003
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200342040-00003

Weitere Artikel der Ausgabe 4/2003

Clinical Pharmacokinetics 4/2003 Zur Ausgabe